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Ischaemic heart disease and cerebrovascular disease are the leading causes of morbidity and 
mortality in the world. The underlying progression of the disease is linked to a reduction 
in the bioavailability of nitric oxide. One factor contributing to this is an increase in the 
production of superoxide radicals. A combination of increased oxidative stress, inappropriate 
lipid metabolism and cell death sets the stage for what will subsequently develop into 
atherosclerosis. The process of atherogenesis can slow down if patients at risk are identified 
early, receive the necessary pharmacological treatment and change to a healthier lifestyle. 
The aim of the following studies was to identify whether the uptake, synthesis and recycling 
of tetrahydrobiopterin (BH4), the essential co-factor of endothelial nitric oxide synthase 
(eNOS), could influence oxidative stress in human vasculature. We also sought to elucidate 
whether endothelin-1 (ET-1), a potent vasoconstrictor, played an important role in oxidative 
stress in human vasculature and the potential mechanisms underlying this influence. 
In Study I, 49 patients with coronary artery disease took part in a placebo-controlled clinical
trial with the aim of determining the mechanisms of exogenous BH4 in relation to vascular
function. Oral BH4 treatment significantly elevates the levels of BH4 in blood, but this effect
is limited by the rapid systemic oxidation of exogenous BH4. The ratio of reduced to oxidised
biopterins in blood and vascular tissue is unchanged by exogenous BH4 treatment, resulting
in no net effect on vascular superoxide production or endothelial function.
In Study II, the aim was to explore the regulation of endogenous BH4 and subsequent effects 
on endothelial function in patients with coronary artery disease. In three clinical models and 
one in vitro model, involving 465 subjects, we observed that an inability to increase vascular 
BH4 synthesis leads to significant impairment of endothelial function. 
In Study III, the aim was to explore the role of  ET-1 in endothelial dysfunction, specifically with 
regard to superoxide production. ET-1 increases superoxide production in human coronary 
artery bypass grafts via a receptor-driven mechanism involving, the largest contributor of 
superoxide in the vascular wall, nicotine amide dinucleotide phosphate (NADPH) oxidase. 
In Study IV, I applied what I had learned from Study I and Study II and sought to further 
delineate whether endothelin-1 influences biopterin homeostasis in both human and animal 
tissues. ET-1 did not have any effect on BH4 in human coronary artery bypass grafts or 
resistance arteries, endothelial cells and mice with an over-expression of ET-1 in the 
endothelium (ET-transgenic mice).   
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SAMMANFATTNING
Ischemisk hjärtsjukdom utgör den vanligaste orsaken till sjukhusvård och död i världen. 
Otillräcklig blodförsörjning av hjärtat till följd av blodpropp eller åderförkalkning 
(ateroskleros) i hjärtats kranskärl är huvudorsaken till mortalitet och morbiditet. Ett 
förstadium till ateroskleros är endoteldysfunktion. En av de viktigaste molekylerna som 
endotelet frigör är kväveoxid (NO). NO bevarar kärlets förmåga att vidga sig adekvat, 
förhindrar blodproppsbildning och inflammation. En annan viktig substans är endotelin-1 
(ET-1), en peptid som i huvudsak agerar i motsatsförhållande till NO. NO skyddar vävnaden 
och ökar blodflödet medan endotelin minskar blodflödet och agerar vävnadsskadande. En 
huvudsaklig orsak till minskad biotillgänglighet av NO är ökad produktion av fria radikaler 
såsom superoxid. 
I denna avhandling har jag huvudsakligen studerat det enzym som producerar NO, endothelialt 
kväveoxidsyntas (eNOS) och närmare bestämt den ko-faktor (tetrahydrobiopterin eller BH4) 
som huvudsakligen avgör huruvida eNOS ska producera NO eller superoxid, då detta enzym 
kan vara en källa för båda. 
I studie I randomiserades 49 patienter med koronarsjukdom som stod på väntelista för bypass 
kirurgi till att få BH4 oralt eller placebo. Patienterna erhöll 2-6 v behandling med BH4 
eller placebo. Före och efter behandlingen testades kärlfunktionen. Oralt BH4 förbättrade 
inte kärlfunktionen. Kärlbitar från operationen studerades och en ökning av BH4 och dess 
biprodukt BH2 i vener observerades. Upptaget av BH4 ökade inte i artärer. Detta resulterade 
i utebliven förändring i förhållandet mellan BH4 och dess biprodukter och därför heller 
ingen minskning på superoxidproduktion, dvs eNOS fortsatte att producera superoxid. 
Sammanfattningsvis visade studien att tillförsel av oralt BH4 ökar tillgängligheten av BH4 
men även BH2, vilket totalt sett resulterar i utebliven förbättring av kärlfunktionen.
Studie II består av fyra delar, i första delen deltog friska försökspersoner, de randomiserades 
till vaccination med salmonella typhi eller placebo och kärlfunktionen mättes före och efter 
vaccinationen. Vaccinationen resulterade i en ökning av BH4 , interleukin 6 och c-reaktivt 
protein i plasma. Kärlfunktionen försämrades akut av vaccinationen. I del två studerades 440 
patienter med kranskärlsjukdom avseende förekomst av en speciell haplotyp av guanosine 
cyclohydrolas (GCH) genen och vi fann att denna var kopplad till endoteldysfunktion samt 
förhöjt c-reaktivt protein. I del tre delades patienter med kranskärlssjukdom upp i en grupp 
med homozygoter för denna GCH haplotyp (XX) och en grupp utan denna haplotyp (OO). 
Dessa fick sedan vaccination med salmonella typhi och kärlfunktion mättes. Patienter 
med haplotypen XX kunde inte öka plasma BH4 och hade en försämrad kärlfunktion efter 
vaccination. I del fyra användes en kärlmodell som jag utvecklade för att studera hur kärlet 
kan producera eget BH4 och hur denna process påverkas av inflammatoriska substanser.  I 
en sådan miljö ökar BH4 i kärlet och detta är direkt kopplat till förbättrad endotelfunktion. 
I studie III studerade jag endotelin-1 och huruvida denna peptid kan öka bildningen av 
fria radikaler i kärl från patienter med kranskärlssjukdom. Endotelin-1 ökar produktionen 
av superoxid och jag kunde härleda detta till att vara medierat via endotelinreceptorer och 
NADPH oxidas som huvudsaklig superoxidkälla. 
I studie IV studerade jag vidare direkta effekter av ET-1 på BH4, den essentiella ko-faktorn 
till eNOS. I denna studie visar jag i olika cell, djur och kärlmodeller att endotelin-1 inte har 
någon effekt på tillgängligheten av BH4 i vävnaden och således är eNOS inte en huvudsaklig 
källa för superoxidbildning i detta sammanhang. 
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1   INTRODUCTION
1.1 ENDOTHELIAL DYSFUNCTION AND CARDIOVASCULAR DISEASE
Ischaemic heart disease and cerebrovascular disease are the leading causes of morbidity and 
mortality in the world. An inadequate or obstructed blood supply to the heart is the cause 
of ischaemia. Endothelial dysfunction refers to the initial stages of the process leading to 
the development of atherosclerosis and is mainly due to the reduced bioavailability of nitric 
oxide (NO) and increased levels of the vasoconstrictor, endothelin-1 (ET-1).1 
Generally, four major mechanisms are described as reducing the bioavailability of NO:
(1)  Reduced endothelial nitric oxide synthase (eNOS) expression
(2)  A lack of substrate (L-arginine) or co-factors (mainly the essential co-factor, tetrahydro-
biopterin; BH4) for eNOS or the presence of antagonist (asymmetric dimethylarginine)
(3)  Reduced eNOS activation and
(4)  Increased consumption of NO due mainly to the increased production of superoxide 
radicals 
Risk factors for cardiovascular disease such as smoking, aging, hypercholesterolemia, 
hypertension, hyperglycaemia and a family history of early atherosclerotic disease are all 
associated with the reduced bioavailability of NO and the subsequent loss of endothelium-
dependent vasodilatation.2 Several studies have now proven that endothelial dysfunction is a 
strong and independent predictor of cardiovascular events.3 
The identification of subjects at risk before clinically evident atherosclerosis is essential 
for the correct management in primary prevention. In this situation, the measurement and 
assessment of endothelial function may be valuable in identifying subjects at risk, as well as 
evaluating treatment effects both in research and in clinical practice. 
In the following chapters, I shall review the sources and mechanisms of superoxide 
production in human vasculature and discuss the importance of these sources in relation to 
clinical practice. I will also highlight the role of ET-1 as a cause of endothelial dysfunction 
based on superoxide production via its interaction with different sources of superoxide. 
1.2 BIOLOGICAL ACTIONS OF REACTIVE OXYGEN SPECIES
The common denominator of all reactive oxygen species (ROS) is that they originate from 
oxygen. As we are immersed in an oxygen-rich environment, it is not surprising that we 
are bound to experience the formation of oxygen radicals. They form as a by-product of 
the electron transport of aerobic respiration in mitochondria or by oxidoreductase enzymes. 
These radicals perform important biological functions such as host defence, the biosynthesis 
of hormones and fertilisation and act as intracellular signaling molecules.
ROS are usually divided into two groups: 
(1) free radicals, such as superoxide, hydroxyl and NO, and 
(2) non-radical derivatives of oxygen, such as hydrogen peroxide and peroxynitrite.
4 
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Oxygen is first reduced to superoxide and superoxide dismutase then promotes further 
reduction to hydrogen peroxide, which can react with metals and form hydroxyl radicals. 
Peroxynitrite is formed through the reaction of superoxide with NO, leading to the reduced 
bioavailability of NO, which in turn leads to endothelial dysfunction. One pathway illustrating 
the role of peroxynitrite formation is through the nitration of prostacyclin synthase and by 
the inhibition of soluble guanylyl cyclase. This is the bedrock upon which the link between 
oxidative stress and endothelial dysfunction rests. 
When superoxide production exceeds innate antioxidant defence systems, cellular damage 
starts to occur such as for example the inhibition of cell growth, the promotion of apoptosis or 
cell death.5 Lipid peroxidation, protein oxidation and DNA damage are usually attributed to 
ROS and they are involved in atherogenesis. Oxidative modifications of proteins may result 
in the formation of nitrotyrosine, which represents a marker of cardiovascular disease.6 7 In 
the atherosclerotic process, ROS can promote oxidised low-density lipoprotein formation, 
stimulate matrix metalloproteinases, increase vascular smooth muscle cell growth and provoke 
inflammatory mediator production, including matrix metalloproteinase-1, intercellular 
adhesion molecule 1 and vascular cellular adhesion molecule 1. The reduced production of 
superoxide leads to a decrease in the recruitment of macrophages to the endothelial surface, 
which will have direct effects on the formation of the atherosclerotic plaque.8
1.2.1 Superoxide signaling in cardiovascular diseases and clinical implications
The links between superoxide signaling and cardiovascular disease states such as coronary 
artery disease and myocardial infarction have been described in a large set of animal studies. 
9 Through the genetic deletion or overexpression of major superoxide sources, such as the 
NADPH oxidase system or antioxidant defence systems such as superoxide dismutases, 
a large body of knowledge has been retrieved in animals and cell models.10 For the past 
decade or so, some of these mechanisms have been studied in humans. Some might argue 
that oxidative stress is not linked to the progression of atherogenesis in human, as almost all 
large clinical trials with oral antioxidants have failed to have any influence on hard endpoints 
and clinical outcomes.11 The results of these trials indicate that oxidative stress is not a one-
directional process. The cascade of reactions initiated by superoxide interacting with pro-
oxidative enzyme systems and an equally wide range of antioxidant defence mechanisms 
makes the arena complex. In this thesis we sought to find mechanistic explanations to the link 
between superoxide production and endothelial dysfunction.  
1.3 SOURCES OF HUMAN VASCULAR REACTIVE OXYGEN SPECIES
The major science underlying our current knowledge of ROS generation in human vasculature 
stems from studies of cultured endothelial, smooth muscle cells and coronary artery bypass 
grafts. The use of bypass grafts has the advantage of being 
(1) accessible for ex vivo mechanistic and functional studies and 
(2) obtained from a patient with manifest atherosclerosis. 
In 2004, Guzik et al. verified NADPH oxidase as the main contributor to ROS generation in 
human saphenous veins. An increase in the expression of the subunits of NADPH oxidase 
was found in vessels from diabetic patients.12 There was also evidence of contribution by 
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eNOS to the overall ROS burden, especially in diabetics. It has been proposed that NADPH 
oxidase and eNOS are involved in intricate crosstalk. In many review articles, initial ROS 
generation from NADPH oxidase is described as a trigger resulting in a series of reactions, 
including the activation of the other enzyme systems.13 These other sources of superoxide are 
mitochondrial ROS and xanthine oxidase (Fig 1). 
1.3.1 Endothelial nitric oxide synthase
The role of eNOS in the development of endothelial dysfunction attracted renewed interest 
when it was understood that this enzyme generates superoxide. The rationale behind this 
phenomenon is now well known. The family of NOS enzymes, eNOS, inducible NOS and 
neuronal NOS, all share an essential need for co-factors BH4, NADPH and the flavins and 
flavin mononucleotide, on top of the substrate L-arginine, to generate NO. Nitric oxide 
synthases are homo dimers and each monomer consists of a reductase domain with binding 
sites for NADPH, flavins, flavin mononucleotide and calmodulin and an oxygenase domain 
containing an iron heme group and binding sites for L-arginine and BH4. Starting from 
NADPH, electrons flow to the flavins in the reductase domain, to the iron of the heme in the 
oxygenase domain. Calmodulin regulates electron flow between the reductase and oxidase 
domain. BH4 appears to be essential to donate electrons to the heme group in the oxygenase 
domain in order to oxidise L-arginine. In the absence of BH4, electron flow from the reductase 
domain is diverted towards molecular oxygen rather than L-arginine, resulting in superoxide 
production rather than NO synthesis. This is the main explanation of eNOS uncoupling. In 
the following sections, I will further discuss the role of BH4 as a key regulator of eNOS.
Fig 1. The largest contribution of vascular superoxide (O2
-) originates from nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase, which is membrane bound. Reactive 
oxygen species (ROS) generated from NADPH oxidase reduce the bioavailability of nitric 
oxide (NO) due to the reaction of NO with O2
- generating peroxynitrite. Peroxynitrite 
oxidizes tetrahydrobiopterin (BH4), leading to reduced BH4 and eNOS uncoupling, which 
means that eNOS produces superoxide instead of NO. Xanthine oxidase and mitochondria 
also contribute to ROS generation in the cell. 
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1.3.2 BH4 and its role as a key regulator of NOS
BH4 belongs to the family of chemical structures called pteridines and it was first described 
in 1895.14  The first description of BH4 was in relation to its role as a co-factor of four aro-
matic amino acid hydroxylases (tyrosine hydroxylase, phenylalanine hydroxylase, tyrosine 
hydroxylase and tryptophan hydroxylase). BH4 is therefore involved in the synthesis of epi-
nephrine, norepinephrine, dopamine and 5-hydroxytryptamine (5-HT or serotonin).  It took 
several decades (1989) for Stuehr et al.15 to describe BH4 as a co-factor for NOS enzymes.
1.3.2.1 Regulation of NOS
A turning point in NO research was the finding that NOS enzymes contain a cytochrome P450 
type heme which enables the activation of oxygen without the co-factor.14 16 BH4 functions as 
an allosteric modulator of arginine binding; i.e. when BH4 is present, the affinity for binding 
arginine to NOS increases. In a pro-inflammatory environment with increased oxidative 
stress, BH4 can be oxidised by peroxynitrite to the non-protonated trihydrobiopterin (BH3) 
radical and then to dihydrobiopterin (BH2) and biopterin (B). 
In the literature, the question of whether BH4 can be oxidised by other ROS has also been 
raised. Due to the chemical properties of these reactants, if superoxide, NO and BH4 are 
present, superoxide will react with NO, first forming peroxynitrite and then the further 
oxidation of BH4. 17 
BH2 has been shown to compete with BH4 to bind to NOS. In endothelial cells with 
oxidative stress, the electron transfer become uncoupled from L-arginine oxidation, leading 
to superoxide being produced from the oxygenase domain (Fig 2). In this setting, BH4 and 
particularly the ratio of BH4:BH2+B become key determinants of eNOS uncoupling and, in 
the long run, eNOS regulation.16  
Fig 2. In conditions of low superoxide and an abundance of L-arginine, endothelial nitric 
oxide synthase (eNOS) produces NO and L-citrulline. In conditions of increased superoxide 
production and the formation of peroxynitrite, BH4 is oxidised, resulting in the reduced 
bioavailability of BH4, the uncoupling of eNOS and production of superoxide.
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Another aspect of eNOS regulation, which will not be dealt with any further in this thesis, 
is whether it is possible that eNOS uncoupling can occur due to a lack of substrate such as 
L-arginine. In cell-free systems, using electron spin trapping, it was reported that L-arginine 
alone is unable to inhibit superoxide release from BH4 free eNOS,18 whereas the addition of 
BH4 was able to reduce superoxide formation without L-arginine.19 In endothelial cells, the 
addition of L-arginine in the absence of BH4 increased eNOS-mediated ROS.20 Furthermore, 
animal studies in which eNOS coupling is restored with the emphasis on L-arginine 
availability have failed to take into account the importance of quantified BH4 and BH2.21
1.3.2.2 De novo synthesis of BH4 and relation to inflammatory stimuli
The de novo synthesis of BH4 (Fig 3) involves the actions of the rate-limiting enzyme, 
guanosine triphosphate cyclohydrolase 1 (GTPCH), encoded by the GCH-1 gene. Animal 
and elegantly designed in-vitro models show a direct correlation between GCH-1, GTPCH 
protein and levels of intracellular BH4.22 One such animal model is the hph-1 mouse with 
constitutively reduced expression of GCH-1. The hph-1 mouse model was produced in 1988 
by screening N-ethyl-N-nitrosurea-treated mice for the presence of hyperphenylalaninemia.23 
In the hph-1 mouse, the relative quantification of GCH-1 mRNA expression correlate directly 
with the protein level and enzymatic activity of GTPCH, along with the reduced synthesis 
of BH4.22 In humans, the relationship becomes more complex and even more so in a pro-
inflammatory environment. 
Fig 3. The de novo synthesis of BH4 is driven by the rate-limiting enzyme, GTP 
cyclohydrolase 1 (GTPCH). In a pro-oxidative setting, GTPCH activity and expression is 
increased due to the influence of inflammatory cytokines such as interferon γ (IFN γ) and 
tumor necrosis factor α (TNFα). Reactive oxygen species (ROS) activate nuclear factor 
kappa B (NF-κB) signalling.
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The regulation of the GCH-1 gene with regards to the influence of inflammatory cytokines 
has been studied in endothelial cells24, leukocytes25 and smooth muscle cells.26 In these studies 
tumor necrosis factor α (TNFα), interleukin-6, lipopolysaccharide (LPS) and hydrogen 
peroxide stimulate BH4 synthesis through increased GCH-1 mRNA. The underlying 
mechanisms have been attributed to the increased activation of NF-κB and the janus kinase 
signal transducer activator of transcription protein (JAK-STAT), which are key inflammatory 
transcription factors.14 
Another pathway which is linked to the process of atherogenesis in the vasculature involves 
the influence of shear stress on GTPCH regulation. Widder et al.27 were able to show that 
GTPCH activity in human endothelial cells was increased 30 fold in areas of laminar shear 
stress, leading to a proportionately significant increase in BH4. The mechanism was the 
casein kinase 2 (CK2)-dependent phosphorylation of GTPCH. Oscillatory stress, which is 
common in curvatures or branching points of the vessel, did not show a similar pattern. 
The current understanding of GTPCH regulation in humans and more specifically in patients 
with coronary artery disease is very limited. This is mainly due to the poor availability of 
relevant tissues. In some studies, attempts have been made to study neopterin (marker of 
inflammation) or biopterin levels in the plasma of these patients and link it to cardiovascular 
events.28 However, these studies are limited due to the intricate relationship between plasma 
and vascular biopterins. Antoniades et al. 29 described an inverse relationship between plasma 
BH4 and vascular BH4 in the bypass grafts of patients with coronary artery disease undergoing 
coronary artery bypass grafts surgery. Patients with high vascular BH4 had bypass grafts with 
better endothelium-dependent relaxation to acetylcholine than patients with low vascular 
BH4. High plasma BH4 was paradoxically associated with impaired endothelial-dependent 
relaxation and low vascular BH4. The authors conclude that plasma BH4 is mainly driven 
by the contribution of BH4 from inflammatory cells and the liver, whereas vascular BH4 is 
driven by the rate-limiting enzyme, GTPCH, which is in turn directly correlated to GCH-1 
gene expression. As a result, it is not passive diffusion which increases BH4 intracellularly 
but rather genetic factors which regulate the increase in BH4 in the endothelium, while the 
loss of vascular BH4 is possibly due to oxidation. What are the consequences of this inverse 
relationship in patients and how can the induction of endogenous GCH be a possible vascular 
defence mechanism?
The mechanism of inducing vascular GCH-1 in patients with coronary artery disease was 
previously not clear and in this thesis we therefore sought to explore this further with a vessel 
model using coronary artery bypass grafts. This model was then further used to explain some 
of the findings of two clinical trials (Studies I and II). 
Another aspect of GTPCH biology is the possibility for GTPCH degradation via proteasomes. 
In a study of high glucose stimulation of human endothelial cells, it was reported that GTPCH 
can be degraded by 26s proteasome.30 This is an aspect which has not been studied in vivo and 
could potentially also influence BH4 availability. 
1.3.2.3 The salvage pathway and biopterin recycling
The salvage pathway (Fig 4) refers to the possibility of maintaining BH4 bioavailability 
through the actions of dihydrofolate reductase (DHFR). This pathway starts with sepiapterin 
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and, via sepiapterin reductase (SR), BH2 is formed. It can undergo reduction back to BH4 
via DHFR. BH2 is able efficiently to replace eNOS-bound BH4, resulting in eNOS uncoup-
ling.31 Interestingly, in a cell model with the genetic knock-down of DHFR and the inhibition 
of DHFR with methotrexate, it was observed that the importance of DHFR appears to be 
more prominent at low levels of GTPCH expression, low levels of BH4 and in conditions of 
high levels of BH2, which correlates well with what is found in patients with coronary artery 
disease.32 
Biopterin recycling refers to the actions of dihydropteridine reductase (DHPR). A deficiency of 
DHPR is an autosomal recessive condition and has been shown to cause hyperphenylalanemia 
or phenylketonuria (PKU) due to BH4 deficiency. BH4 supplementation is therefore used in 
the treatment of PKU. The actions of DHPR with regard to the regulation of eNOS remain 
to be studied. 
1.3.3 NADPH oxidase 
The family of NADPH oxidase (NOX) consists of seven proteins, where NOX1, NOX2, 
NOX4 and NOX 5 have been reported to be expressed in the cardiovascular system. They 
are found in endothelial cells, smooth muscle cells, fibroblasts and phagocytic mononuclear 
Fig 4. The salvage pathway includes the actions of sepiapterin reductase (SR), which 
can reduce sepiapterin to dihydrobiopterin (BH2) in all cells, and dihydrofolatereductase 
(DHFR), which reduces BH2 back to tetrahydrobiopterin (BH4). In a pro-inflammatory 
setting, BH4 is oxidised to BH2 and, in such a setting, the role of DHFR becomes 
interesting as a potential mechanism to sustain BH4. The figure also shows the possibility 
of the oxidation of BH2 to B, which is not part of the salvage pathway but occurs in states 
of low nitric oxide (NO) availability and increased superoxide production. 
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cells.33 NOX 1 and 4 are expressed in vascular smooth muscle cells and NOX2 and 4 are 
found in endothelial cells.34 They are transmembrane proteins, which require interaction with 
a cytosolic activator protein (p47 phox, p67 phox and Rac) in order for ROS generation 
to occur (Fig 5). This interaction has been carefully studied using inhibitors of Rac and 
silencing RNA of the cytosolic activator proteins, showing unanimously that these proteins 
do not produce superoxide without the prior assembly. NOX 4 does not require an activator 
protein and generates ROS (H2O2) constitutively. The consequences of NOX 4-dependent 
ROS are also different in the cell in comparison to the other NOXs, all of which generate 
superoxide. As a result, there is still a great deal to be explored in terms of the roles of the 
different NOXs and their interaction. 
In coronary artery bypass grafts, Guzik et al. were the first to provide evidence that NADPH 
oxidase is a major contributor of ROS in human vessels and that there were differences in 
the expression of the different NOXs in the vascular wall.12 Western blotting and RT-PCR 
analysis of these vessels revealed that p22 phox and cytoplasmic subunits (p67 phox and 
p47 phox) were more abundant in saphenous veins than in mammary arteries. In saphenous 
veins, NOX 2 is mainly found, whereas NOX 4 appears to be more important in mammary 
arteries. NOX 1 was found in very low levels. Interestingly, cardiovascular risk factors such 
as hypertension, hypercholesterolemia, obesity and aging are all linked to the increased 
expression and activity of NOX2.35 
Sorescu et al.33 were able further to explore the cellular sources of intracellular superoxide 
production in atherosclerotic and non-atherosclerotic human coronary arteries. They found 
that all cells are able to produce superoxide, but it is especially high in the shoulder regions 
of the plaque, which are areas with a high degree of inflammation and risk of rupture. They 
Fig 5. Nicotinamide phosphatase (NADPH) oxidase consists of transmembrane proteins 
(heterodimer consisting of gp91 phox and p22 phox) which require interaction with a 
cytosolic activator (p47 phox, p67 phox and Rac1) for the activation and further production 
of superoxide (O2
-).
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also found that superoxide production was low in stable, collagen-rich, macrophage-deficient 
plaques. Monocytes express NOX 2 mRNA 456 times more than endothelial cells. In coronary 
arteries, the group found that NOX 2 was mainly expressed in the adventitia, much less in 
the intimal layer and almost not at all in the medial layer. The severity of atherosclerosis 
was significantly correlated to NADPH oxidase subunit expression, due mainly to the 
infiltration of macrophages.33 In conclusion, patients with coronary artery disease generate 
ROS dependent on NOX and this is closely related to the presence of inflammatory cells in a 
pro-atherogenic environment.
1.3.4 Other sources of superoxide: Mitochondria and Xanthine oxidase
Superoxide is generated at several sites in the electron-transport system, located on the 
inner mitochondrial membrane. Mitochondria related superoxide production is closely 
linked to the energy-generating process of the organelle.36 The electron transport system 
involves five large proteins named complex I-V. The leakage of electrons between these 
complexes is thought to generate superoxide, which is quickly reduced to hydrogen peroxide. 
Mitochondrial superoxide can also react with NO and form peroxynitrite. The regulation 
of mitochondrial ROS will not be reviewed here. The contribution of mitochondrial ROS 
will enhance and stimulate other sources of superoxide, subsequently accelerating the pro-
inflammatory process. It is not surprising then that mitochondrial ROS is linked to the 
activation of pathways such as NF-κB and STAT.
When it comes to xanthine oxidase, it has been shown to reduce molecular oxygen to both 
superoxide and H2O2. The inhibition of xanthine oxidase improves vasodilatation in patients 
with hypercholesterolemia. Due to the lack of sensitive assays which are able accurately to 
measure xanthine oxidase activity very little is known about xanthine oxidase and its role in 
endothelial dysfunction.37 
1.4 ENDOTHELINS 
Endothelins form a family of peptides consisting of three isoforms, ET-1, 2 and 3. Of these 
three, ET-1 is linked to endothelial dysfunction and superoxide production.1 ET-1 is a 21 
amino acid long peptide with vasoconstrictive properties. In healthy vessels it is mainly 
synthesised in endothelial cells from a precursor pre-pro ET-1, which is cleaved into big 
ET-1 and converted to ET-1 by a group of endothelin-converting enzymes.38 The peptide has 
a paracrine/autocrine influence on the vessel. It binds to two G-protein-coupled receptors 
(GPCR), ETA and ETB (Fig 6). ETA is expressed in vascular smooth muscle cells (VSMC), 
cardiomyocytes and fibroblasts.1 
ETB is found on both VSMC and endothelial cells. The binding of ET-1 to the ETA receptor 
leads to vasoconstriction, cell growth, cell proliferation and cell adhesion.39 Binding to the ETB 
receptor on endothelial cells results in the release of NO and vasodilatation. The ETB receptor 
also functions as a clearance receptor, via which ET-1 is eliminated from the circulation.40 
NO downregulates the expression and secretion of ET-1. Since ET-1 is immediately secreted 
and not kept intracellularly, it binds to the ETB receptor, resulting in NO production via cyclic 
GMP which in turn reduces the further secretion of ET-1. ETB receptors are also located on 
vascular smooth muscle cells and mediate vasoconstriction. 
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As pointed out below there is a substantial change in the expression and function of the 
ET receptors in various pathophysiological conditions, resulting in an altered biological 
response.41 Increased levels of circulating ET-1 in pathological states such as coronary artery 
disease or heart failure may be due to the reduced clearance of ET-1 by the ETB receptor, as 
well as the increased production of ET-1 in VSMC and inflammatory cells. ET-1 has been 
shown to increase ROS generation; superoxide, peroxynitrite and H2O2. 
In the following sections, I shall review the mechanisms of ET-mediated superoxide 
production which will vary depending on tissue and disease state.
1.4.1 Mechanisms of ET-mediated superoxide production
It is well known that the influence of ET-1 differs between vascular beds, where larger arteries 
have a different path of activation in comparison with smaller resistance arteries.40 This 
difference also influences the mechanisms behind increased superoxide production. There is 
a large variety and discrepancy in the findings relating to the source of superoxide, the tissue 
and the ET receptors that are involved in ET-mediated superoxide production.42-58. In Table 
1, the most important publications on ET-mediated superoxide production are summarised. 
In this section, I shall give a short review of the current knowledge relating to ET-mediated 
superoxide production and the contribution of NADPH oxidases and eNOS uncoupling. The 
emphasis will be placed on possible mechanistic explanations of ET-mediated superoxide 
production. 
Fig 6. Endothelin-1 (ET-1) is mainly synthesised in endothelial cells in healthy vessels 
and acts via two G-protein-coupled receptors, ETA and ETB. These receptors can be found 
on endothelial cells, vascular smooth muscle cells (VSMC) and adipocytes. The action of 
ET-1 in a healthy artery results in vasodilatation. In oxidative stress, there is an increase in 
ET-1 production and a reduction in the bioavailability of nitric oxide (NO), which results 
in vasoconstriction. 
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Table 1. Summary of current scientific articles examining the potential source of ET-
mediated superoxide production.
1st author Species Tissue Receptor ROS detection (In vitro/
In vivo)
Result Ref
Li Rat Carotids ETA DHE and 
Lucigenin CL
In vivo 
and in-
vitro
ET-1 increases superoxide via ETA 
and NADPH oxidase
42
Loomis Rat Aorta Lucigenin CL In vitro NADPH oxidase and eNOS 
uncoupling contributes to ET-1 
mediated superoxide. Dual 
blockade of ET-1 could reduce ET-1 
mediated superoxide
43
Yilmaz Rat Thoracic 
aorta rings
Not 
studied
None In vitro ET-1 mediated vasoconstriction is 
connected to NADPH oxidase and 
PARP pathway
44
Dong Human HUVEC ETB CM-H2 DCFDA In vitro ET-1 increases H2O2 via ETB, 
increases cellproliferation
45
Zheng Rat Carotids ETA Lucigenin CL In vitro GTPCH gene transfer increases 
BH4 and improves vascular redox. 
46
Montezano Human EC Not 
studied
Lucigenin CL In vitro NOX5 is involved in ET-1 mediated 
superoxide. Independent of Rac1. 
47
Deng Rabbit Atrial and 
ventricular 
myocytes
ETA None In vitro Endothelin signalling via NADPH 
oxidase
48
Viel Rat Aorta and 
resistance 
arteries
ETA DHE In vitro Involvement of ETA receptor in 
superoxide generation via xanthine 
oxidase and mitocondria in aorta 
and resistance arteries. 
49
Touyz Human VSMC Not 
studied
CMH2DCFDA 
fluorescence
In vitro ET-1 mediates superoxide 
production via mitochondrial ROS
50
Dammanahalli Human HAAEC ETB DCFH-DA,
DHE
In vitro ET-1 increases superoxide NADPH 
oxidase: via ETB- Pyk2-Rac1-
Nox1 Pathway
51
Romero Rat Aortic 
rings
ETA DHE In vitro ET-1 increases superoxide via 
NADPH oxidase, increase of 
p47 phox expression, involving 
c-Src activation and ERK ½ 
phosphorylation
52
Duerrschmidt Human HUVEC ETB Coelenterazine 
CL
In vitro ET-1 increases superoxide via ET-
B-NADPHoxidase (gp91 phox)
53
Sarkar Bovine PASMC ETA SOD inhibitable 
cytochrome c 
reduction assay
In vitro ET-1 increases superoxide via ETA-
NADPH oxidase and induces an 
increase in proMMP-2activation via 
NADPH oxidase-PKC-p38MAPK-
NF-KB signaling.
54
Sanchez Rat Penile 
arteries
ETA Lucigenin CL In vitro ET-1 increases superoxide via 
ETA- NADPH oxidase
55
Ergul Human Saphenous 
vein
Not 
studied
DHE and 
lucigenin CL
In vitro ET-1 increase superoxide in SV but 
not via NADPH oxidase
56
Meyer Mouse Carotid 
artery
Not 
studied
None In vitro Vascular responses to ET-1 are 
NADPH oxidase dependent and 
mediated by inducible NOX-1/ and 
or NOX 2 isoforms, incl increased 
expression of p47 phox. 
57
Callera Rat Aorta, 
mesenteric 
arteries 
and heart
ETA Lucigenin CL In vitro ET-1 mediates increased 
superoxide independent of NADPH 
oxidase, nor Xanthine oxidase or 
eNOS uncoupling. Possible role for 
mitochondrial ROS
58
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1.4.1.1 NADPH oxidase
To date, there are four main mechanistic possibilities describing the role of NADPH oxidase 
in ET-mediated superoxide production. 
(1) The correlation between ET-mediated vasoconstriction and NADPH oxidase activity43 57 
(2) The increased expression of ET receptors and the ratio of ETA to ETB
57 59 
(3) The increased expression of NADPH oxidase subunits in the vasculature in relation to 
ET-152 
(4) Activation of down-stream signaling of G-protein coupled receptors such as mitogen 
activated protein kinase (MAPK)54 ERK 1/252 pathways, poly ADP ribose polymerase 
(PARP)  pathway44 and Pyk2-Rac1-Nox1-pathway39 51.  
The link between ET-1 contractility and NADPH oxidase was shown in a mouse model 
with the aim of studying the role of aging.57 Aging increased ET-1 contractility, ET-receptor 
expression with a switch towards increased ETB and the increased expression of the NADPH 
oxidase subunit, p47 phox. The authors conclude that vascular responses to ET-1 are NADPH-
oxidase dependent and are mediated by the inducible NOX1 and/or NOX2 isoforms, but also 
increased vascular p47phox gene expression may explain the increase in NADPH oxidase 
activity induced by ET-1.
In atherosclerotic vessels, several studies have demonstrated that an increase in ETB to ETA 
receptor expression occurs, as well as an increase in the levels of big ET-1 and endothelin- 
converting enzyme, indicating an increase in the synthesis of ET-1.59 It has also been shown 
that it is possible that inflammatory cells are able to modulate the switching of ET receptor 
subtypes from ETA to ETB in vascular smooth muscle cells. In human atherosclerotic vessels, 
there was an increase in the immunoreactivity of ET-1 and ETB receptors in both non-foamy 
and foamy macrophages, T lymphocytes in fatty streaks and fibrous plaque lesions. In 
addition, medial SMCs located just beneath the foam cell lesions revealed a higher intensity 
of ETB receptor immunoreactivity than those located beneath the normal-looking intima 
without foam cells. In fibrous plaques, intimal smooth muscle cells near foam cells showed 
an increase in the density of ET receptors with predominant ETB immunoreactivity. In the 
areas where vascular smooth muscle cells expressed an increased density of ETB receptors, 
ET-1 immunoreactivity was also enhanced.60 These findings suggest that oxidative stress may 
be mediated by both ETA and ETB receptors on VSMCs in human atherosclerosis. 
Regarding GPCR signaling, a recent study by Sarkar et al. describes a model in pulmonary 
artery smooth muscle cells which highlights a few interesting mechanistic pathways involved 
in ET-mediated superoxide production. In this model, ET-1 increases superoxide via the ETA 
receptor involving NADPH oxidase and signaling through the protein kinase C (PKC)-
>MAPK->NF-Kβ pathway.54 
Romero et al.52 studied ERK1/2 pathways in rat aortic rings and they were able to show that 
ET-1 increases superoxide production via an increase in p47 phox expression involving a 
non-receptor tyrosine protein kinase (c-Src) and ERK1/2 phosphorylation. 
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A recent intracellular downstream signaling pathway connected to oxidative stress in relation 
to atherosclerosis is poly (ADP ribose) polymerase (PARP-1). In thoracic rings from rat, ET-1 
induced endothelial dysfunction which could be restored after incubation with PEG-SOD 
(superoxide scavenger), an inhibitor of NADPH oxidase (apocynin) and a PARP inhibitor. 
In addition, Western blots on vessel rings which had been stimulated with ET-1 showed an 
increase in the expression of PARP.44 Collectively, these findings suggest that ET-1 may 
contribute to oxidative stress through NOX in a variety of different tissues. 
 1.4.1.2 eNOS uncoupling
To date, very few studies have been able to show a link between eNOS uncoupling and ET-
mediated superoxide production. Of these, only three studies43 46 61 are related to ET-mediated 
superoxide production and the possible involvement of eNOS uncoupling.  
Loomis et al.43 and Zheng et al.46 have explored this possible link to some degree. Loomis et 
al. found that adding BH4 to rat aortic rings incubated with ET-1 led to reduced superoxide 
production and improved relaxation responses to acetylcholine, indicating an improvement 
in endothelial function.  
Zheng et al.46 reported that the gene transfer of GTPCH restored arterial GTPCH activity 
and BH4 levels, resulting in reduced superoxide and improved endothelium-dependent 
relaxation and basal NO release in deoxycorticostereone (DOCA)-salt rats. The authors 
concluded that BH4 deficiency resulting from ET-induced superoxide via an ETA/NADPH 
oxidase pathway leads to endothelial dysfunction, while the gene transfer of GTPCH I 
reverses BH4 deficiency and endothelial dysfunction by reducing superoxide in low renin 
mineralocorticoid hypertension. However, BH4 may have acted as an anti-oxidant in these 
studies, thereby reducing superoxide production and improving endothelial function. Direct 
effects on eNOS coupling were not studied.
Furthermore, the direct effect of ET-1 on BH4 is unknown. Romero et al.61 studied the 
influence of quercetin (a flavonol found in fruit and grains) on ET-mediated superoxide 
production due to NADPH oxidase and eNOS uncoupling. In aortic rings, ET-1 impaired 
vasorelaxation to acetylcholine which can be restored with an inhibitor of NADPH oxidase 
(apocynin), partially by superoxide dismutase (SOD) but not sepiapterin. ET-1 significantly 
increased superoxide as measured by lucigenin-enhanced chemiluminescence in aortic rings, 
which could be inhibited with apocynin and sepiapterin. The authors concluded that ET-
mediated superoxide production originates from NADPH oxidase and eNOS uncoupling. 
It is, however, evident that adding sepiapterin did not improve endothelial function and it 
is therefore not clear whether eNOS uncoupling is a causal explanation of ROS-induced 
endothelial dysfunction in the case of ET-1. 
The very few studies and the lack of conclusive data give an indication of the need for more 
studies to explore the influence of ET-1 on eNOS uncoupling. 
         eNOS and endothelial dysfunction
23
1.5 SUMMARY 
Endothelial dysfunction is a critical step in the development of atherosclerosis. Oxidative 
stress plays an important role in reducing the bioavailability of NO through direct oxidation 
and through decreased production from eNOS. The generation of excessive amounts of ROS 
leads to not only reduced NO but also oxidative modifications of key proteins which can 
initiate and sustain disease progression. Sources of ROS are eNOS uncoupling, NADPH 
oxidase, mitochondria and xanthine oxidase.  
In this thesis, I have sought to explore further the regulation of eNOS in coronary artery 
disease using tissue from patients undergoing coronary artery bypass surgery. In this tissue, 
NADPH oxidase and eNOS uncoupling are the most important sources of ROS. eNOS 
is closely regulated by its essential co-factor, BH4, and, more importantly, the ratio of 
BH4:BH2+B. The availability of BH4 is influenced by oxidative processes of the cell but 
also by synthesis and salvage pathways. 
In the pro-atherogenic environment, ET-1, a vasoconstrictor, is increased and influences 
NO bioavailability through the generation of ROS. ET-1 acts through its receptors with an 
intricate downstream signaling system. Whether ET-1 influences NADPH oxidase and eNOS 
uncoupling is not fully clear and we have sought to study this further.
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2   HYPOTHESIS AND AIMS
The main hypothesis of this thesis was that eNOS and endothelial function is regulated by 
the availability of BH4.
Four studies were designed with the specific aim of investigating: 
(1) Exogenous BH4 and effects on endothelial function in patients with coronary artery 
disease (Study I)
(2) The regulation of endogenous BH4 and subsequent effects on endothelial function 
in patients with coronary artery disease (Study II)
(3) The source of ET-mediated superoxide production and the involvement of an ET-
receptor-dependent mechanism in patients with coronary artery disease (Study III)
(4) BH4 availability during increased ET-mediated superoxide production and effects 
on endothelial function (Study IV)
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3   MATERIALS AND METHODS
3.1 STUDY SUBJECTS
All the investigations were carried out in accordance with the Declaration of Helsinki and 
were approved by the regional ethics committee at Karolinska Institutet or Oxford University. 
Study subjects were patients admitted to the Cardiothoracic Unit at John Radcliffe Hospital, 
Oxford, UK, awaiting coronary artery bypass surgery. Recruitment took place at the hospital 
one day before surgery except in the clinical trial (study I). The patients were informed about 
the purpose of the study and the possible risks of participating. All patients gave their written 
consent to take part in the studies. Baseline characteristics for all studies are shown in Table 
2. In Study 4, endothelial function is assessed in resistance arteries from six healthy women 
undergoing elective caesarean section at Karolinska University Hospital, Sweden. 
3.1.1 Study I
A total of 55 patients agreed to donate tissue from surgery. Of these, 49 patients took part 
in the clinical trial and the remaining six patients were only recruited for the ex vivo vessel 
experiments. 
3.1.2 Study II
A total of 445 patients and 20 healthy subjects were included in the study. Of these, 19 
patients were recruited for the ex vivo vessel experiments. 
3.1.3 Study III
We recruited 90 patients. The inclusion criteria were coronary artery disease in need of elective 
or subacute coronary artery bypass surgery and the exclusion criteria were emergency CABG 
and unwillingness to participate. 
3.1.4 Study IV
We recruited 41 patients. The inclusion criteria were elective and subacute coronary 
artery bypass grafts surgery and the exclusion criteria were emergency bypass surgery and 
unwillingness to participate. 
3.2 CLINICAL ASSESSMENT OF VASCULAR FUNCTION
3.2.1 Brachial flow-mediated dilation and magnetic resonance imaging
Flow-mediated dilation (FMD) is the method that is most widely used for measuring 
endothelial function and specifically the ability of arteries to respond to endothelial NO 
release during reactive hyperaemia (flow mediated).62 A blood pressure cuff on the forearm 
is used to occlude the flow in the brachial artery for five minutes. When the pressure of the 
cuff is released, the arterial flow increases, giving rise to increased NO release from the 
endothelium. The difference in the diameter of the brachial artery before and after occlusion 
is then measured using ultrasound (Study II) or, in the case of Study I, magnetic resonance 
imaging. In order to measure endothelium-independent dilation, subjects received 200 µg 
of glyceryl trinitrate sublingually. Endothelium-independent dilation was calculated as 
Ruha Cerrato
26
the percentage increase between the baseline luminal area and the maximum luminal area 
following the administration of glyceryl trinitrate. 
Leeson et al.63 reported good agreement and reproducibility between the two modalities and 
here is a summary of the advantages of each modality:
The advantages of MRI are:   
(1) Full three-dimensional visualisation of the vessel, enabling the imaging plane to be 
placed perpendicular to the vessel in a reproducible location
(2) The ability to measure other parameters of vascular structure and function (aortic 
and carotid distensibility) as part of the same examination. 
The advantages of ultrasound are:
(1) A higher temporal resolution than MRI, allowing more precise determination of the 
‘peak of the curve’ of dilation
(2) Lower cost
(3) Better subject tolerability (no claustrophobia).
Table 2. Baseline characteristics of study subjects from Studies I-IV
Study  I Study  II Study 
III
Study 
IV
Placebo 400
mg/d
700
mg/d
Ex 
vivo
Part I Part 2 Part 3 Part 4
Vacc Placebo OO XO XX OO XX Ex 
vivo
Subjects (n) 19 14 16 6 10 10 280 85 11 40 10 19 90 41
Age (SEM) 68 69 68 71 29 31 65 67 67 60 66 68 68 68
Risk factors
Diabetes 
mellitus (%) 26 36 25 17 0 0 29 26 23 23 20 10 28 27
Hypertension 
(%) 68 79 69 50 0 0 68 78 76 72 80 68 70 63
Smokers (%) 11 14 25 17 30 40 40 33 38 51 48 26 16 12
BMI (SEM) 27 30 27 30 25 25 28 28 28 29 27 28 28 29
Medication
Aspirin (%) 100 79 88 67 0 0 77 80 85 80 80 63 79 51
Statin (%) 95 93 100 83 0 0 82 82 80 26 90 78 88 95
ACEi and/or 
ARB (%) 84 79 56 50 0 0 68 67 67 74 60 72 59 81
B blocker (%) 84 71 56 83 0 0 77 75 65 76 70 73 70 85
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The raw data yielded by ultrasound and MRI are not the same. Ultrasound measures changes 
in vessel diameter in the longitudinal plane, whereas MRI measures changes in vessel cross-
sectional area. The FMD value measured by ultrasound will translate to a higher FMD value 
as compared to measured by MRI, as vessel area is proportionate to the square of vessel 
radius.63
A detailed description of the MRI protocol can be found in the published article relating to 
Study I.
3.2.2 Arterial stiffness 
Local NO bioavailability regulates arterial elasticity in humans in vivo. Arterial stiffness is 
correlated to cardiovascular risk.64 MRI can be used to measure arterial stiffness. Blood flow 
data can be acquired simultaneously and the path length (the distance between the two aortic 
locations) can be measured precisely. In Study I, MRI was used to measure arterial stiffness 
(aortic/carotid distensibility and aortic pulse wave velocity). 
 
All the above-mentioned methods for assessing vascular function in vivo were performed by 
collaborators in Oxford, UK. 
3.3 CORONARY ARTERY BYPASS GRAFTS 
3.3.1 Handling and dissection
Internal mammary artery (IMA) and human saphenous vein (SV) segments were collected 
from the surgical theatre at John Radcliffe Hospital, Oxford, UK. The segments were 
immediately gently flushed with oxygenated ice-cold Krebs-Henseleit buffer and then 
immersed in the buffer while awaiting transport to the lab. Perivascular fat and connective 
tissue surrounding the vessel were gently removed with surgical tools. The vessels were then 
immediately used for vascular superoxide measurement, biopterin measurement, vasomotor 
studies or ex vivo incubation. 
3.3.2 Protocol ex vivo experiments
The model for ex vivo experiments was developed using vein and mammary grafts from an 
additional 30 patients. These initial experiments laid the foundation for a protocol which could 
then be used in Studies I and II. Because of the nature of biopterins, conditions must be such 
that the external influence of the oxidation of BH4 and endotoxin or bacterial infiltration, for 
example, is not present. The very first experiments in somewhat unsterile conditions revealed 
a huge increase in BH4 overnight (24 h), indicating the presence of bacteria or fungi. For this 
reason, all further experiments were performed under sterile and endotoxin-free conditions. 
Vessel segments were immersed in oxygenated cold Hanks Buffered Saline Solution (HBSS, 
consisting of sodium bicarbonate without calcium chloride and magnesium sulphate) buffer 
with 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid (HEPES) in theatre, after which 
the vessel segments were gently flushed. Within 15 minutes, the segments were transferred to 
the laboratory. The vessels were dissected and cut into 3 mm thick rings. One ring from each 
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patient was immediately snap frozen and labelled time 0. The remaining vessel rings were 
placed in six-well cell-culture plates with sterile HBSS containing HEPES, 1% penicillin 
streptomycin and 1% amphotericin B and further placed in a cell incubator with 95% oxygen 
(O2) and 5% carbon dioxide (CO2). Concentrations of antibiotics and anti-fungi were carefully 
determined in a set of experiments in order to ensure that they did not interfere with biopterin 
homeostasis. The use of HBSS was optimal, as normal endothelial cell media usually contain 
serum and other additives which can interfere (as seen on the read-out of biopterin levels).  
The vessels were incubated in a cell incubator and checked macroscopically after 24 h for 
signs of infection. They were then snap frozen and kept at -80°C until analysed for biopterin 
measurements, gene expression and protein. In order to make sure that the conditions under 
which the vessels were kept did not affect endothelial function, a few vessels were transferred 
to an organ bath to evaluate endothelial function by quantifying the relaxation response to 
ACH at time 0 vs 24 h. It then became clear that the vessels that had been kept overnight had 
an increased response to ACH in comparison to time 0. So, in a first series of experiments, 
I sought to explain this finding and link it to the substantial increase in BH4; whether it 
was endothelial specific, whether it was driven by synthesis or salvage pathway, as possible 
mechanistic explanations.
In order to study whether the increase in BH4 was endothelial specific, a few vessel rings 
underwent endothelial denudation and were then stored at -80°C for subsequent analysis. 
The question of synthesis vs salvage pathway could be studied using an inhibitor of GTPCH, 
diamino-6-pyrimidine (DAHP), and an inhibitor of DHFR, methotrexate. When the model 
appeared to deliver robust data, it could then be used to answer more specific questions 
within the clinical trials (Study I + II). 
3.3.2.1 Incubation schedule Study I
Vessel segments from six patients were incubated for 30 min in oxygenated Krebs Hepes 
Buffer at 37°C either in buffer alone or in the presence of BH4 (100 nmol/L, Schirks Labo-
ratories, Jona, Switzerland), BH4 plus the antioxidant, dithioerythritol (DTE, 1 mmol/L) or 
BH2 (100 nmol/L, Schirks Laboratories). Samples of incubation media and vessel rings were 
stored at -80°C prior to the quantification of BH4, BH2 and biopterin by high-performance 
liquid chromatography (HPLC) with electrochemical detection for BH4 and fluorescent for 
BH2 and B.
3.3.2.2 Incubation schedule Study II
Four sequential rings of SV and IMA from the same patient were incubated for 24 h ex vivo 
in the absence (control) or presence of the GTPCH inhibitor, DAHP (1 mmol/L), with or 
without stimulation by an inflammatory cytokine cocktail consisting of TNFα (4 ng/mL) 
plus IL-6 (25 ng/mL) plus LPS (80 ng/mL). After incubation, vascular rings (SV only) were 
transferred to an organ bath to evaluate endothelial function by quantifying the vasomotor 
responses to acetylcholine ACH and the endothelium-independent vasodilator, sodium 
nitroprusside (SNP). Some vessel rings were kept at -80°C for the quantification of BH4, 
BH2 and biopterin and GCH mRNA expression. 
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3.3.3 Organ bath
Endothelium-dependent and -independent dilations were assessed with isometric tension 
studies. Vessel rings were equilibrated and passively pre-tensioned to 3 g, an optimal resting 
tension that was determined in baseline studies of the contractile response to potassium 
chloride (KCl). After precontraction with phenylephrine (3x10-6 mol/L), vasomotor responses 
to the endothelium-dependent vasodilator, ACH (10-9 to 10-5 mol/L), were quantified in the 
four equally sized segments from the same vessel, as described in the previous paragraph. 
Finally, relaxations to the NO donor, sodium nitroprusside (SNP, 10-10 to 10-6 mol/L), were 
evaluated in the presence of the NOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME 
100 µmol/L).
3.3.4 Vascular superoxide measurement
The quantification of reactive oxygen species in vascular tissue is difficult for the following 
reasons. 
(1)  Superoxide is generated in very small amounts due to instant reactions with surrounding 
molecules and very effective scavenging by for example superoxide dismutases and NO. 
(2)  Some probes are able to generate superoxide themselves due to redox cycling and 
(3) The inability of most assays accurately to quantify the generation of intracellular 
superoxide.65 
Among the large variety of assays lucigenin-enhanced chemiluminescence and dihydroethi-
dium (DHE) have been proven to have high enough sensitivity and specificity for detection 
of superoxide in vascular tissue.66 
3.3.4.1 Lucigenin-enhanced chemiluminescence
This method uses the cell-permeable chemiluminescent probe, bis-N-methylacridinium, or 
lucigenin chemiluminescence, which releases a photon when it is exposed to superoxide. This 
emission of light can be detected by a luminometer. Briefly, superoxide reduces lucigenin to 
its cation radical, which reacts with a second superoxide molecule to form dioxetane emitting 
a photon.66 This method has been used extensively as an indicator of intracellular superoxide 
in many different vessel models (for references, please see Table 1). The method has been 
challenged due to the fact that it can react with oxygen when there are high concentrations 
of lucigenin, creating a system for redox cycling originating from the tissue itself. At low 
concentrations (<5 µmol/L) of lucigenin, this type of redox cycling is not seen. This has been 
proven with electron paramagnetic resonance.67
 
Lucigenin-enhanced chemiluminescence was used to measure vascular superoxide in paired 
segments of SV and IMA in Studies III and IV. The segments were divided into four to six 
rings, each approximately 3 mm thick, depending on size, weight ranging from 6-20 mg/
ring. The vessel segments were opened longitudinally to expose the endothelial surface and 
equilibrated in oxygenated (95% O2/5% CO2) Krebs-HEPES buffer (pH 7.4) at
 37°C. As a 
measure of eNOS coupling, we determined NOS-derived production in paired segments, 
which was estimated as the difference in superoxide production after 20 min of incubation 
with the NOS inhibitor, L-NAME, alone 68 or followed by incubation with ET-1 (0.1 nM) for 
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45 min. The vessel segment was then quickly transferred to a luminometer containing low-
concentration lucigenin (5 µM) in order to measure superoxide production. In a separate set 
of experiments, additional rings were analysed after 20 minutes’ pre-incubation with the ETA 
receptor antagonist, BQ123 (1 μM), alone, or in combination with the ETB receptor antagonist, 
BQ788 (1 μM; dual BQ), the NADPH oxidase inhibitor, apocynin, the mitochondrial ROS 
inhibitor, rotenone, and the xanthine oxidase inhibitor, oxypurinol, followed by ET-1 (0.1 nM) 
for 45 min. At the end of these experiments, the NADPH-stimulated superoxide production 
was estimated 10 min after NADPH (0.1 mM) was added, as previously described 68
3.3.4.2 Dihydroethidium
The oxidative fluorescent probe, DHE, is used in detecting superoxide in intact tissues. Its 
lipophilic nature makes the permeation of cell membranes possible. After reacting with 
superoxide (forming 2OH-E+), this blue fluorescent probe will oxidise to ethidium bromide 
(E+) and bind to DNA, which stains the cell nucleus red. The analysis of the tissue and 
the fluorescence is measured with confocal microscopy.69 The reaction forming 2OH-E+ can 
also occur via other pathways involving cytochrome P450 and this method is therefore a 
qualitative rather than a quantitative indicator of superoxide.66 
In situ superoxide production was determined in vessel cryosections with the oxidative 
fluorescent dye, DHE, as previously described 70. Paired vessel segments were incubated in 
the presence or absence of ET-1 (0.1nM) in Krebs-HEPES buffer for 45 min at 37°C and then 
snap frozen in tissue tek optimum cutting temperature (OCT) liquid in preparation for further 
cryosections. Cryosections (30 µm) were equilibrated in the presence or absence of ET-1 for 
30 min at 37°C and then exposed to DHE (2 µM) for five minutes. Fluorescence images of the 
endothelium (x63, Zeiss LSM 510 META laser scanning confocal microscope) were obtained 
from each vessel quadrant. Segments of vessel rings (with and without ET-1) were analysed 
in parallel with identical imaging parameters. DHE fluorescence was quantified by automated 
image analysis with Image-Pro Plus software (Media Cybernetics, Bethesda, Md, USA). 
3.3.5 Quantification of biopterins 
BH4, BH2 and biopterin (B) levels in vessel tissue lysates, homogenates from the lungs 
and aortas of transgenic (ET-TG) mice with ET-1 overexpression in the endothelium, 71, cell 
lysates, and plasma lysates were determined by HPLC, followed by electrochemical (for BH4) 
and fluorescent (for BH2 and B) detection. All HPLC measurements were performed at the 
Channon Laboratory at the Department of Cardiovascular Medicine, University of Oxford, 
where the method has been extensively validated for several years 16. Samples were injected 
onto an isocratic HPLC system and quantified using sequential electrochemical (Coulochem 
III, ESA Inc., UK) and fluorescence (Jasco, UK) detection. HPLC separation was performed 
using a 250 mm, ACE C-18 column (Hichrom, UK) and mobile phase, comprising 50 mM 
sodium acetate, 5 mM citric acid, 48 µM ethylene diamine tetra-acetic acid (EDTA) and 160 
µM DTE (pH=5.2) (all ultrapure electrochemical HPLC grade) at a flow rate of 1.3 ml/min. 
BH4 was measured directly by the electrochemical detector (background currents of +500 
nA and -50 nA were used for the detection of BH4 on electrochemical cells E1 and E2 
respectively). 7,8-BH2 and biopterin were measured as separate chromatographic peaks, 
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in the same sample, using a Jasco FP2020 fluorescence detector, serially connected to 
the electrochemical detector. The quantification of BH4, BH2 and B was performed by 
comparison with external standards. All the samples were loaded in the HPLC auto-sampler 
in random batches (of up to 12 samples at a time). Each batch was run with an individual 
standard curve for BH4, BH2 and B. Biopterin levels were expressed as pmol/mg of tissue 
or protein.
3.3.6 Quantification of GTPCH activity
GTPCH activity was measured by HPLC analysis after iodine oxidation. Samples were 
incubated with GTP to produce 7,8 dihydroneopterin triphosphate. Oxidation by potassium 
iodide and iodine forms neopterin triphosphate and dephosphorylation by alkaline phosphate 
produces neopterin, which can be detected by HPLC fluorescent detection. Snap-frozen tissue 
samples (30 mg) underwent three freeze-thaw cycles and cell pellets were freeze thawed 
in lysis buffer (0.1 M Tris, 0.3 M KCl, 2.5 mM EDTA and 100 μM phenylmethylsulfonyl 
fluoride pH 7.8). 250 μl of tissue and cell lysates were incubated for one hour at 37°C with 
50 μl of 10 mM GTP in the absence of light. Samples were then oxidised with 10 μl of 
potassium iodide/iodine 0.1 M and deproteinated with 10 μl 1 M hydrochloric acid for one 
hour at room temperature in the absence of light. The reaction was stopped by the addition 
of 10 μl 0.1 M ascorbic acid. 1 M sodium hydroxide and 16 U/ml of alkaline phosphatase 
were added for one hour at 37°C in the absence of light. Samples were injected onto an 
isocratic HPLC system and quantified using fluorescence (JASCO, UK) detection. HPLC 
separation was performed using a 250 mm, ACE C-18 column (Hichrom, UK) and mobile 
phase comprising 50 mM sodium acetate, 5 mM citric acid, 48 μM EDTA and 160 μM DTE 
(pH 5.2) at a flow rate of 1.3 ml/min. All the chemicals that were used were ultra-pure HPLC 
grade. The quantification of neopterin was carried out by comparison with external standards 
and normalised for sample protein content. Subsequently, the protein concentration of each 
sample was measured using the BCA Protein Assay kit (Pierce, USA). 
3.3.7 Reverse transcription polymerase chain reaction
Segments of vessels were immersed in trizol before they were snap frozen. Trizol is a phenol-
based liquid which maintains ribonucleic acid (RNA) integrity during homogenisation. 
The segments were then thawed and 500 μl of trizol was added to each vessel segment, 
after which they were homogenised for one minute on ice. To each homogenate, 200 μl of 
chloroform was added. The samples were shaken vigorously for at least two minutes. They 
were left at room temperature and then centrifuged at 13K for 15 min at 4°C. The aqueous 
phase was removed and 700 μl of 70% ethanol was added. The samples were subsequently 
added to RNeasy columns (Qiagen, UK), where total RNA binds to the membrane of the 
column and contaminants are washed away. Two different RNeasy kits (Qiagen, UK) were 
used, depending on sample size; for samples of < 5 mg, an RNeasy micro kit was used, while 
RNeasy mini kits were used for larger samples. Qiagen provides a protocol for RNeasy kits 
which was followed. RNA was converted into cDNA (superscript II reverse transcriptase, 
Invitrogen), then subjected to a quantitative real-time polymerase chain reaction using the 
TaqMan system (Applied Biosystems; assay ID GCH Hs00609198-m1, assay ID GAPDH 
Hs02758991-g1, assay ID eNOS Hs01574659-m1) and analysed on an Icycler IQ (Bio-
Rad). Relative expression was calculated using the 2-ΔΔCT method (normalised to endogenous 
control GAPDH).
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3.3.8 Western blotting
Protein was extracted from frozen segments of SV and IMA with lysis buffer (50 mmol/L Tris, 
pH 7.5, 150 mmol/L NaCl, 0.1% sodium dodecyl sulphate, 0.5% deoxycholate, 1% Nonidet 
P-40) containing protease inhibitors (Complete; Roche) and 1 mmol/L phenylmethylsulfonyl 
fluoride. Protein lysates (5 to 15 μg) were separated by electrophoresis on 4% to 12% NuPAGE 
Bis-Tris gels (Invitrogen, Carlsbad, Calif). Rabbit anti-human GTPCH (1:2000) was kindly 
provided by Gabriele Werner-Felmayer, Inst. for Medical Chemistry and Biochemistry, 
Austria. eNOS and GAPDH were detected using mouse monoclonal antibodies (BD 
Biosciences, San Jose, Calif, and Chemicon International, Temecula, Calif, respectively). 
Mouse anti-rabbit glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 1:5000, Millipore, 
USA) and mouse anti-bovine α-actinin (1:2000, Sigma Aldrich Inc) were used to confirm 
equal protein loading. Protein bands were visualised by chemiluminescence (Supersignal 
Pierce, USA).
3.3.9 Determination of protein content
Sample protein content was measured using the BCATM protein assay kit (Pierce, USA). 
Standards were prepared from bovine serum albumin (BSA, 2 mg/ml stock, Sigma Aldrich 
Inc). Standards, samples and an assay buffer blank (12 μl) were mixed with a 20 mg/ml 
solution of iodoacetamide (12 μl) (Sigma Aldrich, Inc) and incubated at 37°C for 15 min. 
Reagent A and B were mixed 50:1 respectively and 480 μl was added to all standards, samples 
and blank. Tubes were incubated for 30 min at 37°C. Standards, samples and blank (2 x 240 
μl) were added to a 96-well plate and read at 562 nm. The concentration of protein within 
each sample was calculated using the standard curve.
3.4 RESISTANCE ARTERIES FROM HEALTHY SUBJECTS 
3.4.1.1 Study subjects, handling and test of vasomotor responses 
Healthy women undergoing planned elective caesarean section were asked to donate 
subcutaneous fat. All the women gave their oral and written consent. A subcutaneous 
fat sample (dimensions:  L, <50 mm; W, <20 mm; T, <10 mm) was collected in ice-cold 
Physiological Salt Solution (PSS; composition, see below), repeatedly rinsed with ice-cold 
PSS and stored for the remainder of the procedures on ice. A small piece of the biopsy (20 x 
20 mm) was then pinned on a silicone substrate in ice-cold PSS (exchanged every 10 min) 
and subcutaneous, resistance arteries (RA) were isolated by micro-dissection. After the RA 
were trimmed of perivascular fat and connective tissue, two wires (diameter 0.04, stainless 
steel) or 0.025 mm (tungsten) were carefully inserted into the lumen. The resistance artery 
with the wires was then transferred to one of the wells of a four-channel myograph (Danish 
Myo Technology, www.dmt.dk) and mounted on specimen holders to record transverse 
isometric force, as previously described.72
3.5 ANIMAL MODELS
In this thesis, we present data from a mouse model with the overexpression of human 
preproET-1 specifically in the endothelium, the ET-TG mouse.71 The mouse has three times 
higher vascular tissue ET-1 mRNA and seven times higher ET-1 plasma levels in comparison 
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with WT, indicating that the increase in gene expression was also linked to the increased 
secretion of  ET-1. There were no significant differences in blood pressure or heart rate between 
ET-TG and WT mice. Resistance arteries from the ET-TG mouse have a significantly reduced 
relaxation response to ACH and a blunted contraction response to ET-1 in comparison with 
WT mice. No difference in contraction to norepinephrine was seen. ETB receptor mRNA 
and protein were significantly increased in comparison with WT. With regard to superoxide 
production, NADPH oxidase activity was measured with lucigenin CL, showing significantly 
increased activity in comparison with WT. Moreover, the NADPH oxidase subunit gp91 
phox protein was increased, indicating a link between ET-mediated superoxide production 
and NADPH oxidase.71 Resistance arteries were also tested for relaxation responses to ACH 
in the presence and absence of L-NAME, vitamin C and Tiron in the original publication. 
The ET-TG arteries showed an improvement in relaxation responses in the presence of 
vitamin C, indicating a role for ROS and, with L-NAME, there was an inhibitory response 
but still slightly better than in WT, indicating that there might be a small possibility of eNOS 
uncoupling. 
We had the opportunity to quantify biopterins in the aorta, lung and plasma from the ET-TG 
mouse. We used the same protocol as described in 3.3.5. We did not study the resistance 
arteries, as these vessels are so small that quantifying biopterins becomes near impossible. 
3.6 ENDOTHELIAL CELLS
3.6.1 sEnd.1 cells and HUVEC
sEnd.1 cells are mouse endothelioma cells73 and they have a substantially increased expression 
of GCH and an abundance of BH4. We quantified BH4, BH2 and biopterin in the presence 
and absence of ET-1. They were also used as positive controls for GTPCH activity assays 
and Western blots. Human umbilical vein endothelial cells (HUVEC) were purchased from 
Lonza and grown to confluence in a flask with endothelial cell-specific medium. After three 
passages, the cells were used to measure biopterins in the presence and absence of ET-1. 
3.7 STATISTICAL ANALYSIS
The results are presented as the mean and standard error of the mean (SEM), apart from 
Study III, where all the data are the mean and standard deviation (SD). All variables were 
tested for normal distribution using the Kolmogorov-Smirnov test. Non-normally distributed 
variables were log transformed for analysis. For the ex vivo experiments in Studies I and II, 
one- or two-factor ANOVA was used, followed by the Bonferroni post-hoc test to compare 
variables between groups. For the vasomotor studies, vasorelaxation curves were compared by 
two-way ANOVA for repeated measures. All the tests were two-tailed and values of p < 0.05 
were considered significant. All the statistical tests were performed with either SPSS (Studies I 
and II) or Graph Pad prism (Studies III and IV).
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4   RESULTS
4.1 ENDOGENOUS BH4 AND ITS REGULATION
4.1.1 Model for ex vivo incubations of SV and IMA
A model for ex vivo incubations was created for SV and IMA (unpublished data, for details: 
methods section 3.3.2). This model was further used in Study I and Study II. The incubation 
of SV overnight (24 h) without any stimuli resulted in a significant increase in BH4 (Fig. 7A; 
endothelialised SV: n=24, p<0.0001, endothelium de-nuded vessels: n=5) but not in BH2 
(Fig. 7B, SV n=24; p>0.05, endothelium de-nuded vessels: n=5). This increase in BH4 is 
linked to an increase in the activity of the rate-limiting enzyme, GTPCH (Fig. 7E, SV with 
endothelium, n=11, p<0.0001). It is also linked to an increase in the mRNA expression of 
GCH (Fig 7F, SV, n=6) and GTPCH protein expression (Fig 7H, SV, representative figure of 
n=2). eNOS protein expression was also increased (Fig 7H, SV, representative figure of n=2).
Further, a subset of vessels (Fig 7C-D, n=3 of SV and IMA) were incubated with the GTPCH 
inhibitor, DAHP, and the DHFR inhibitor, methotrexate. In this small set of experiments, 
there appears to be an indication (although not significant due to the small-scale observation) 
that the increase in BH4 may be related to synthesis rather than to the salvage pathway, as the 
increase in BH4 could be blocked by the GTPCH inhibitor (synthesis) and not by the DHFR 
inhibitor (salvage). 
Of the incubated vessels, a subset of vessels from three patients was randomly selected 
and responded well to acetylcholine (Fig 7G). The vasomotor studies were performed to 
ensure that the vessels were not completely damaged by the prolonged incubation time. The 
model was used to address the questions of endogenous vs exogenous BH4 (Study I) and the 
regulation of endogenous BH4 in response to inflammatory stimuli (Study II).
4.1.2 Study I
4.1.2.1 Background 
In Study I, 49 patients were randomised to receive low-dose (400 mg/d) or high-dose (700 
mg/d) BH4 or placebo for two to six weeks prior to coronary artery bypass surgery. Vascular 
function was quantified using FMD with MRI before and after treatment, along with plasma 
BH4 levels. Vascular superoxide, endothelial function and BH4 levels were determined in 
segments of SV and IMA. Oral BH4 significantly increased BH4 levels in plasma and SV 
but not IMA. BH2 was also increased in plasma, SV and, if the patient groups of the two 
doses were put together, also IMA. There was no significant difference in either total vascular 
superoxide production or NOS-derived superoxide production between placebo- and BH4-
treated subjects in either SV (p=0.7) or IMA (p=0.12). The quantification of vascular function 
by MRI at baseline and after treatment with either placebo or BH4 revealed no effect of oral 
BH4 treatment on brachial flow-mediated dilation (p=0.325) or arterial stiffness. Samples of 
SV for an ex vivo organ bath displayed no difference in endothelium-dependent relaxation 
to acetylcholine or endothelium-independent relaxation to sodium nitroprusside between 
groups (data to be found in the original publication).74 The ex vivo experiments were therefore 
performed to clarify the fate of exogenous BH4 in vascular tissue. 
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A B
C D
E F
Fig 7. Pilot data from the ex vivo vessel model. A. Tetrahydrobiopterin (BH4) in  saphenous 
vein (SV) incubated overnight, 24 h, with endothelium (n=24, 24 h vs 0 with endothelium: 
p<0.0001) and endothelial de-nuded (n=5). B. Dihydrobiopterin (BH2) in SV with 
endothelium (n=24, not significant) and endothelial de-nuded (n=5). C. BH4 in SV (n=3) 
in the presence and absence of the GTP cyclohydrolase inhibitor (GTPCH), diamino-6-
pyrimidine (DAHP), and an inhibitor of dihydrofolate reductase (methotrexate or MTX). D. 
BH4 in internal mammary artery (IMA) (n=3) after incubation in the presence and absence 
of inhibitors GTPCH and dihydrofolatereductase (DHFR). E. GTPCH activity (neopterin), 
in SV with endothelium (n=11, p<0.0001). F. GCH mRNA in SV all layers (n=6). 
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4.1.2.2 Ex vivo experiments
In order to investigate the fate of exogenous BH4 in human vascular tissue and also to further 
study mechanistic aspects relating to the influence of oxidation and biopterin uptake, the 
following experiments were made; segments of SV from an additional six patients were 
incubated for 30 min under the following conditions: buffer alone (control), BH4 (100nM), 
BH4 (100nM)+DTE, and BH2 (100nM). Samples of incubation media were taken before and 
after incubation of the vessel. 
G
H
Fig 7 G. Relaxation responses in saphenous vein (SV) (0 vs 24 h, n=3). H. Western blots of human 
GTP cyclohydrolase (GTPCH), endothelial nitric oxide syntase (eNOS) and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) protein expression loading control. Human GTPCH 
protein expression in SV. Representative images of n=2. Positive control: hepatocytes (hepG2) 
and fibroblast cell line with GTPCH over-expression (tetGCH), negative control sEnd.1 cells 
which expresses only mouse GTPCH. The positive controls were intentionally loaded with less 
protein due to the large amount of GTPCH proteins in these cells.
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The quantification of BH4 in the incubation 
media revealed that BH4 is depleted by the 
end of the experiment (Fig 8A). Pre-values 
showed almost no BH2, which then increased 
partially towards the end. Vascular BH4 only 
increased when added in combination with an 
antioxidant (Fig 8B), incubation with BH4 
led to an increase in BH2 levels (Fig 8C) and 
the BH4/BH2+B ratio (Fig 8D) was reduced 
in the BH4 group even in the presence of an 
antioxidant. 
4.1.3 Study II
4.1.3.1 Background
To summarise, this study consisted of four 
parts.
Part 1: 20 healthy individuals were ran-
domised to Salmonella Typhii vaccination (a 
model of low-grade inflammation) or placebo 
in a double-blind study. In addition, plasma 
biopterins, IL-6 and CRP were measured, as 
well as FMD of the brachial artery using ul-
trasound. The outcome was a significant in-
crease in IL-6 (p<0.01) and CRP (p<0.05), as 
expected, and a significant reduction in FMD 
of approximately 50% at eight hours (p<0.01). 
The intervention elicited a two-fold increase 
in plasma biopterins (p<0.01). 
Part 2: A functional haplotype (X haplotype) 
in the GCH1 gene, encoding GTP-cyclohydro-
lase 1, was associated with signifi cantly redu-
ced FMD using ultrasound (p<0.05) and high 
levels of CRP (as an indicator of systemic 
inflammation) in 440 coro nary artery disease 
patients. The higher the CRP, the poorer the 
outcome on FMD and higher plasma biopte-
rin levels, if the patient also had the GCH X 
haplotype.
Part 3: 50 patients identified with coronary 
artery disease and divided according to GCH 
haplotype underwent the same inflammatory 
insult as in Part 1. Briefly, the presence of 
the GCH X haplotype made it impossible 
to increase BH4 in response to vaccination 
and they had a 60% reduction in FMD 
in comparison with patients without the 
haplotype (OO). 
Fig 8. Ex vivo incubations of saphenous vein 
rings (n=6) for 30 minutes with exogenous 
tetrahydrobiopterin (BH4) examining the 
uptake of BH4 from the systemic circulation 
and the impact of oxidation. The conditions 
were control: buffer alone, BH4, BH4 100 
nM plus dithioerythritol (antioxidant) and 
BH2 100 nM. A. Exogenous BH4 was totally 
depleted in the incubation media, while the 
addition of antioxidant was able to inhibit the 
oxidation partially. B. and C. Incubation with 
BH4 significantly increased tissue BH2, but 
there was no increase in tissue. D. The ratio of 
tissue BH4:BH2+B was reduced in comparison 
to control, even in the presence of antioxidant 
(values are expressed as mean ± SEM *p<0.05 
vs control, and ¶ p<0.05 vs BH4 alone). 
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Figure'6)1:'Ex#vivo'incuba0on'of'vessel'rings'with'exogenous'biopterins'
Saphenous* vein* rings* (n=6* subjects)* were* incubated* for* 30*minutes* under* the*
following* experimental* condi?ons:* Control,* buﬀer* alone;* BH4,* BH4* 100* mM;*
BH4+DTE,*BH4*100*mM*plus*dithoerythritol* (DTE,*an?oxidant)*1*mM;*BH2,*BH2*
100*mmol.*Samples*of*incuba?on*media*were*stored*at*the*beginning*and*end*of*
the*experiment.*Panel*A:*Exogen us*BH4* in* the* incuba?on*medium*was* totally*
depleted* by* the* end* of* he* experiment;* the* addi?on* of* DTE* provided* par?al*
protec?on* from* oxida?on.* Panels* B* and* C:* Incuba?on* with* BH4* signiﬁcantly*
increased*?ssue*BH2* levels* compared* to*c ntrol,*but*only* increased*?ssue*BH4*
levels*in*the*pres nce*of*DTE;*incuba?on*with*BH2*resulted*in*a*larger*increase*in*
?ssue*BH2*but*no*increase*in*?ssue*BH4.*P nel*D:* *Incuba?on*in*exogenous*BH4*
resulted* in* a* signiﬁcant* reduc?on* in* ?ssue* BH4/(BH2+B)* ra?o* compared* to*
control,* even* in* the* presence* of* DTE.* Values* are* expressed* as* mean±SEM.*
*p<0.05*vs*control;*¶p<0.05*vs*BH4*alone.*

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4.1.3.2 Ex vivo model
Part 4: An ex-vivo model was used to evaluate the effect of cytokine stimulation on GCH1 
expression, vascular BH4 and relaxation responses to acetylcholine. This ex-vivo model 
refers to the one described in 3.3.2. 
Fig 9 summarizes the findings from the effects of cytokine stimulation on SV and IMA. 
Endogenous BH4 was significantly increased in SV and IMA which had been exposed to 
cytokines (TNFα 4ng/ml, IL-6 nM and LPS 80ng/ml) in relation to control and these vessels 
also had an enhanced relaxation response to acetylcholine. The increase in endogenous BH4 
was linked to a significant increase in GCH mRNA expression in SV and IMA. When co-
incubation occurred with the GTPCH inhibitor, DAHP, the increase in BH4 or the enhanced 
relaxation response to ACH could no longer be seen, indicating the critical relationship 
between GTPCH and BH4 synthesis. 
4.2 ENDOTHELIN-1 AND EFFECTS ON SUPEROXIDE AND BIOPTERINS 
In Studies III and IV, we sought to explore whether ET-1 influences superoxide production 
and biopterin homeostasis in human vessels. 
4.2.1 Study III
4.2.1.1 ET-mediated superoxide production
A dose-ranging study revealed a marked increase in superoxide production by ET-1 in IMA at 
0.1 nM (Fig 10A; p<0.001). ET-1 at the threshold dose of 0.1 nM increased superoxide both 
in IMA (Fig 10B; p<0.0001) and in SV (Fig 10C; p<0.05). The delta increase in ET-mediated 
superoxide production was significantly greater in IMA compared with SV (Fig 10D; p<0.05). 
DHE staining revealed an increased signal in all layers of the vessel in comparison to control 
but more so sub-laminally, suggesting the involvement of smooth muscle cells (Fig 11). 
4.2.1.2 Receptor-mediated superoxide production and sources of ET-mediated superoxide 
production
As the next step in the exploration of ET-mediated superoxide production in IMA, we wanted 
to analyse whether the effect was receptor dependent and the sources of superoxide that were 
involved. Segments of IMA were incubated in the presence and absence of ET-1 (0.1nM) 
and inhibitors such as BQ123 (ETA receptor inhibitor), Dual BQ (BQ123+BQ788, ETA+ETB 
inhibitor), L-NAME (inhibitor of NOS), rotenone (inhibitor of mitochondrial ROS), diphenyl-
eneiodonium (inhibitor of NADPH oxidase, or flavin-containing enzymes), disodium 4,5-dihy-
droxy-1,3-benzenedisulfonate (tiron, superoxide scavenger). The increase in vascular superox-
ide was significantly blocked by ETA and ETB receptor blockers (n=15 vs n=17, p<0.05), DPI 
(n=9, p<0.001) and tiron (n=6, p<0.001), suggesting that the effect was receptor dependent 
and that the main source of ET-mediated superoxide production was NADPH oxidase. Fig 12.
4.2.2 Study IV
As a continuation of Study III, we sought in Study IV to further explore whether ET-mediated 
superoxide production involves eNOS. In this study, we used HUVEC, sEnd.1 cells, vessel 
grafts, an ET-TG mouse model with the overexpression of ET-1 in the endothelium and 
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Fig 9. Incubation of saphenous vein (SV) (A) and internal mammary (IMA) (B) in the absence 
and presence of cytokine stimulation tumor necrosis factor a (TNFα), interleukin-6 (IL-6) and 
lipopolysaccharide (LPS) induces a significant elevation in vascular tetrahydrobiopterin (BH4), 
an effect that was prevented by diamino-6-pyrimidine (DAHP, GTP cyclohydrolase inhibitor). 
Similarly, cytokine stimulation led to a significant increase in GCH-1 mRNA in both SV (C) and 
IMA (D). Cytokine stimulation leads to increased vasorelaxation to acetylcholine (ACH) in SV 
(E) which is reduced in the presence of DAHP. It had no effect on vasorelaxation in response to 
sodium nitroprusside (SNP) (F). Values are expressed as the mean ± SEM *p<0.05 vs control.
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Fig 10 A. Dose-ranging study of endothelin-1 (ET-1), in internal mammary (IMA), 45 min, 
n=8. B. Effect of ET-1 (0.1nM) on vascular superoxide (O2-) in IMA, n=33. C. Effect on 
ET-1 (0.1nM) on vascular O2- in saphenous vein (SV). D. Delta increase in vascular O2- in 
IMA vs SV. Values are expressed as the mean ± SD, *P<0.05, **p<0.001,*** p<0.0001. 
C D
A B
A B
Fig 11 A. Internal mammary artery (IMA) control. B. IMA+ET-1. 
Effect of ET-1 (0.1nM) incubation of vascular superoxide (O2-) in a representative example 
of IMA (n=3), as determined by dihydroethidium (DHE) fluorescence (red staining indicated 
with white arrows, green staining represents basal autofluoresence). 40x magnification. 
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resistance arteries from women undergoing planned caesarean section. This gave us the 
opportunity to study biopterin homeostasis in many different tissues and models. 
We found that, in repeated experiments in HUVEC, there was no significant effect on BH4 or the 
ratio of BH4:BH2+B following incubation with ET-1 (Fig 13 A: 1.54±1.7 vs 1.68±1.8, p =0.8 
and the ratios 2.25±3.32 vs 3.07±4.6; p=0.06). Since HUVEC have very low levels of BH4, at 
the limit of detection, we wanted to study the possible interaction of ET-1 with eNOS in sEnd.1 
cells that have a high expression of GTPCH and BH4. The rationale was to study whether ET-1 
influences biopterin homeostasis in a high intracellular BH4 environment. However, there was no 
significant effect by ET-1 on BH4 or the ratio in sEnd.1 cells (results not shown). 
Further, we wanted to investigate whether ET-1 influences biopterin homeostasis in vessels 
from patients with coronary artery disease. The rationale was that the production of ET-1 
in human atherosclerotic vessels is increased and we saw in Study III marked ET-mediated 
superoxide production. We therefore wanted to explore whether some of this effect was 
Fig 12. In a series of paired vessel experiments, internal mammary artery (IMA) was in-
cubated in the presence of endothelin-1 (ET-1 0.1 nM) and the following inhibitors of ET 
receptors BQ 123 and BQ788 and of sources of superoxide NG-nitro-L-arginine methyl ester 
hydrochloride (L-NAME), diphenyleneiodonium (DPI), rotenone, tiron. Only ET-1 block-
ade, DPI and tiron were able significantly to inhibit ET-1-mediated superoxide. All values are 
the mean ± SEM, *P<0.05, **p<0.001,*** p<0.0001.
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mediated via direct effects on biopterins. In IMA (Fig 13C; n=10, p=0.4) and SV (Fig 
13C, n=12, p=0.8), there was no significant effect from 45 or 240 min incubation of ET-1 
(0.1µM) on BH4 levels. Superoxide was also measured in IMA in the presence and absence 
of L-NAME in order to detect eNOS uncoupling as a source of ET-mediated superoxide 
production. There was no significant difference in L-NAME inhibitable superoxide between 
ET-1 (0.1nM) and control (Fig 14A, n=12). We also studied the role of NADPH oxidase and 
found that NADPH oxidase-dependent superoxide production could be inhibited by BQ123 
(ETA receptor antagonist), in line with earlier findings in Study III (Fig 14B). Furthermore, 
we investigated whether transgenic mice with ET-1 overexpression in the endothelium and 
verified endothelial dysfunction had any effect on biopterin homeostasis as a consequence of 
increased NADPH oxidase activity. In the ET-TG mouse, there was no significant difference 
Fig 13. A. Quantification of tetrahydrobiopterin, BH4, in human umbilical vein endothelial 
cells (HUVEC)  incubated with endothelin-1 (ET-1) in a dose-ranging study. (n=3 batches, 18 
observations). B. In ET-transgenic (ET-TG) mice there was no significant difference in vascular 
BH4 aortas ET-TG (n=18) vs wild type (n=22) or in pulmonary tissue (n=22). C. Vascular BH4 in 
saphenous vein (SV, n=12 for 45 min and for 240 min, n=6) and internal mammary artery (IMA, 
n=10 for 45 min and n=9 for 240 min) in the presence and absence of endothelin-1 (ET-1). Values 
are mean ± SEM, **p<0.001 refers to IMA vs SV. 
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in intracellular BH4 or the ratio of BH4:BH2+B in comparison to WT: aortas, lungs and 
plasma were examined (Fig 13B).
ET-1 has previously been shown to induce endothelial dysfunction in humans.41 As a final 
set of functional experiments, we studied the effect of ET-1 on endothelial function and 
whether BH4 was able to prevent ET-mediated endothelial dysfunction in human resistance 
arteries. We observed a striking effect of ET-1 in resistance arteries in subcutaneous fat 
harvested from pregnant women undergoing caesarian section, with a significant reduction in 
relaxation to ACH (Fig 14C; n=5, p<0.0001) in comparison with norepinephrine (NE, n=6). 
Endothelial function in these vessels was not restored by BH4 in combination with DTE 
(n=6), suggesting that this endothelial dysfunction was not mediated by eNOS uncoupling.  
Fig 14 A. NG-nitro-L-arginine methyl ester hydrochloride (L-NAME) inhibitable fraction of 
vascular superoxide in internal mammary artery (IMA) incubated with endothelin-1 (ET-1) 
for 45 min (n=12, not significant). Determined by lucigenin-enhanced chemiluminescence. 
B. Nicotine amide dinucleotide phosphate (NADPH) oxidase activity in saphenous vein (SV) 
in the presence and absence of the ET-1 and ETA receptor blocker, BQ123 (n=8, *p<0.05 
control vs ET-1 + BQ123, and # p<0.05: BQ123+ET-1 vs BQ123 alone). C. ET-1 in resistance 
arteries with a significant reduction in relaxation to acetylcholine (ACH) (n=6, p<0.05) in 
comparison with norepinephrine (NE, n=6). ET-1 induced endothelial dysfunction was not 
restored with tetrahydrobiopterin (BH4), n=5. All values are mean ± SEM. ***p<0.0001.
C
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5   GENERAL DISCUSSION
The main hypothesis of this thesis was that eNOS and endothelial function is regulated by 
the availability of BH4.
Four studies were designed with the specific aim of investigating: 
(1) Exogenous BH4 and effects on endothelial function in patients with coronary artery 
disease (Study I)
(2) The regulation of endogenous BH4 and subsequent effects on endothelial function 
in patients with coronary artery disease (Study II)
(3) The source of ET-mediated superoxide production and the involvement of an ET-
receptor-dependent mechanism in patients with coronary artery disease (Study III)
(4) BH4 availability during increased ET-mediated superoxide production and effects 
on endothelial function (Study IV)
The main findings of this thesis are the following:
•	 In a randomized placebo-controlled study oral BH4 does not improve endothelial 
function due to no net change in the ratio of BH4: BH2+B in patients with coronary 
artery disease.
•	 Vascular BH4 is linked to improved endothelial function in patients with coronary 
artery disease. Inflammation in the vascular wall increases the expression of GCH-
1 gene leading to improved vascular function. This is a response to systemic 
inflammation which leads to increased oxidative stress and chronically to endothelial 
dysfunction. The bioavailability of vascular BH4 is linked to the expression of 
GCH-1 gene. 
•	 ET-1 increases superoxide in patients with coronary artery disease via receptor-
dependent mechanism which involves NADPH oxidase. 
•	 ET-1 mediated superoxide does not have any effect on BH4 availability and 
does not change the ratio of Bh4: BH2+B in favor for eNOS uncoupling. ET-1 
mediated superoxide induced endothelial dysfunction cannot be explained by eNOS 
uncoupling. 
5.1 BIOPTERIN UPTAKE AND RECYCLING
The pharmacologial supplementation of BH4 in human have been studied in different 
settings: acute infusion in the brachial artery75-77 or coronary artery78-80 and also as oral 
administration81 82. High doses of BH4 were needed in the intravenous interventions in order 
to achieve improved endothelial function. It has been questioned whether the high dose is 
linked to unspecific antioxidant effects of BH4. 
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Of the oral supplementation studies only one was-placebo-controlled81, patients received 
BH4 during 4 weeks and there was an improvement in NO mediated endothelial function, 
the lowering of plasma F-isoprostanes in patients receiving BH4 is an indication of reduced 
oxidative stress systemically. However, there was no measurement of vascular BH4 nor any 
study confirming that eNOS coupling was the causal explanation of improved endothelial 
function. In reviewing the literature, questions regarding oral BH4 supplementation and links 
to endothelial function still remain unanswered. 
What is the reliability of oral BH4 reaching its target organ, restoring eNOS coupling and 
improving endothelial function? The target organ in this case is the vasculature and more 
specifically the coronary circulation, the provided agent an essential co-factor of eNOS, 
BH4, and through the use of well-validated instruments the read out was assessment of 
endothelial function. This was the setting of Study I. The findings were that oral BH4 did 
not reach its target, i.e. did not increase in arteries (in this case mammary arteries) nor 
was eNOS coupling increased (measured indirectly as reduced superoxide) and there was 
subsequently also no change in endothelial function as determined by flow-mediated dilation 
using magnetic resonance imaging (MRI). The story could possibly end here. How does 
translational thinking, involving ex vivo models, assist in the process of understanding BH4 
biology? The ex vivo vessel model used in this study made it possible to study the mechanistic 
background to BH4 uptake in the vasculature. The experiments showed that the incubation 
of BH4 in an in-vitro setting leads to an increase in BH2. The explanation of this is the rapid 
oxidation of BH4. When BH4 is incubated together with DTE, a potent antioxidant, BH4 can 
be preserved, but the effect did not include BH2, which increases irrespective of DTE, i.e. 
oxidation continued and it is possible that the effect of DTE then diminishes over time. In 
addition to combining BH4 with an antioxidant, there are other possible ways of ensuring the 
delivery of BH4 via liposomal packaging. A recent ischemic-reperfusion intervention in rat 
hearts83 showed a markedly reduced infarct size in rats that had received liposomal BH4, due 
to reduced oxidative stress and increased NO as measured by staining, suggesting improved 
eNOS coupling. Although the measurement of NO can be questioned, it is still a promising 
method to ensure BH4 delivery in a pro-oxidative setting. 
As discussed earlier in this thesis, it has been seen in studies with purified eNOS that it is the 
BH4:BH2+B ratio which is a more important determinant of eNOS uncoupling than absolute 
levels of BH4.19 It is therefore not surprising that, although BH4 levels increased substantially 
in SV, the same thing applied to BH2, resulting in an unchanged ratio and therefore also no 
effects on eNOS coupling. In this model, we were unable to see that BH2 is able to recycle 
back to BH4 via DHFR and increase the level of BH4. Although DHFR activity was not 
measured, there was no increase in vascular BH4 and, in the pilot model of incubations of SV, 
the main explanation of increased BH4 levels was related to synthesis rather than recycling. 
In contrast studies with cell cultures, for example, Sawabe et al.84 show that exogenous BH4 
is not taken up by the cell, but, if sepiapterin is given, the cell takes up BH2 and increases 
BH4 through a salvage pathway. This was not seen in the ex vivo experiments. Interestingly, 
the pilot model showed a significant increase in endogenous BH4 in SV but no increase in 
BH2. Endogenous BH4 does not appear to undergo the same oxidation process as oral BH4. 
Another question is why there was a significant increase in BH4 in SV but not in IMA. This 
needs to be studied further to determine whether uptake differs between veins and arteries. 
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One very important aspect of Study I is the detailed study of the fate of BH4 from circulation 
(plasma) to vessel, giving new insights into the intricate reality of BH4 uptake, oxidation and 
recycling. At the same time, some of the limitations are connected to the ex vivo experiments, 
as biopterin biology is not the same and cannot be compared with an in vivo setting. For 
example, the oxidation of vascular BH4 will be different ex vivo, the rate of oxidation will 
probably be higher and the possibility of self-generating superoxide will also be more likely 
in hyperoxia (which is the case in the organ bath). 
5.2 INFLAMMATION INCREASES ENDOGENOUS BH4
Cell models have shown that GCH-1 expression is increased by stimulation with inflammatory 
cytokines: IFNγ85, TNFα86, and IL-1ß87.  When it comes to atherogenesis and the pro-
inflammatory systemic influence in patients with coronary artery disease, the complexity 
increases. A large clinical cohort showed that high plasma BH4 is linked to impaired 
vascular function due to low vascular BH429 and, in transplant patients, vascular injury due 
to inflammatory stress is related to reduced eNOS expression and increased eNOS activity88, 
a paradoxical finding. How do you address the influence of low-grade inflammation on the 
expression and actions of GCH-1 in humans?
 
In creative models, Study II addresses this question. Study II is a large multi-faceted study 
exploring the complex associations between impaired endothelial function, inflammation 
and plasma and vascular biopterins. The study highlights the role of endogenous BH4 as a 
vascular defence mechanism and specifically GCH-1 expression in relation to endothelial 
function and pro-inflammatory stimuli in healthy, diseased and ex-vivo settings. 
The novel findings of this study suggest that
(1) Plasma and vascular biopterins are regulated differently in their respective 
compartments
(2) Plasma biopterins increase in relation to acute inflammation and are correlated with 
impaired vascular function. The increase in plasma biopterins is due to the increased 
release of BH4 from hematopoietic cells and the liver and not because of increased 
BH4 from the endothelium. 
(3) Vascular biopterins increase as a direct consequence of increased GCH-1 gene 
expression. Increased vascular biopterins are related to improved vascular func-
tion, but this does not necessarily occur in vivo in the setting of atherosclerosis, 
as patients with coronary artery disease had increased plasma BH4 and impaired 
endothelial function. It is the inability of the endothelium to increase vascular BH4 
during systemic inflammation which is linked to impaired endothelial function.
One important limitation of this study is the artificial inflammatory setting, both in vivo with 
vaccination and ex vivo with a cocktail of inflammatory cytokines. Is it comparable and are 
the results applicable in a clinical setting? For example, in the ex-vivo experiments, LPS 
was used. It is mainly found in cases of septic shock, so do we get the same increase in 
endogenous BH4 without LPS? This was not studied. However, in the pilot model, it was 
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clear that the significant increase in BH4 occurred over time without stimulation, so it might 
be possible that this was due to inflammatory cells in the vascular wall. Further studies would 
be needed to examine the occurrence of inflammatory cells, the presence of inflammatory 
cytokines and also the engagement of transcriptional modifications such as the involvement 
of NF-Kβ, as well as antioxidant defence mechanisms involving nuclear factor erythroid 
2-related factor (NRF-2) in an unstimulated vessel.
5.3 ENDOTHELIN-1 AND VASCULAR SUPEROXIDE
ET-1 has been found to be increased in patients with coronary artery disease both in plasma 
and in the expression of endothelin-converting enzyme in atherosclerotic vessels.41 Moreover, 
when it comes to certain risk factors such as hypertension, ET-1 has been found to mediate 
superoxide production, resulting in the reduced bioavailability of NO.89 Linking ET-1 to 
oxidative stress is not in any way a new concept. Table 1 summarizes the current studies 
addressing this link. Our aim in Studies III and IV was specifically to study the role played by 
ET-1 and oxidative stress in coronary artery disease having the necessary access to vascular 
tissue, which has not been studied before. Does ET-1 increase superoxide in coronary artery 
disease and what are the mechanisms underlying this? In contrast to a large set of animal and 
cell studies, this has not been explored. We found that ET-1 markedly increases superoxide in 
coronary artery bypass grafts as determined by lucigenin-enhanced chemiluminescence. In 
order to investigate whether ET-1 mediates superoxide production via a receptor-dependent 
pathway, we exposed paired segments of IMA to ET-1 in combination with its receptor 
antagonists, BQ123 (ETA) alone or in combination with BQ788 (ETB). In-vitro studies show 
that both receptors are able to contribute to superoxide  production.42 45 In our study, we 
demonstrate a clear reduction in ET-induced superoxide production by selective ETA receptor 
blockade and no additional effect of dual ETA/ETB receptor blockade. These observations 
suggest that ETA is the predominant receptor mediating arterial ROS production. 
It is not clear which enzymatic source of superoxide causes ET-mediated superoxide  production 
and we therefore sought to study this further. Since the inhibition of basal superoxide has been 
studied in detail 90, we sought to focus on the inhibition of ET-induced superoxide production. 
In this study, ET-induced superoxide production is significantly inhibited only by tiron, a 
superoxide scavenger, and DPI, an inhibitor of flavin-dependent enzymes such as NADPH 
oxidase, xanthine oxidases and NOS. The specific inhibition of NOS, xanthine oxidases and 
mitochondrial enzymes did not inhibit ET-induced superoxide-, indicating that it is unlikely 
that these enzyme systems contribute to ET-induced superoxide production. Accordingly, we 
conclude that NADPH oxidase is likely to have contributed substantially to the superoxide 
production that was observed following incubation with ET-1. This is in accordance with a 
previous report which demonstrated that ET-1 increases vascular superoxide generation via 
NADPH oxidase in a model of low-renin hypertension 42. However, in 2005, Ergul et al56. were 
unable to detect any increase in NADPH-oxidase-mediated superoxide production following 
ET-1 incubation in SV. This difference may be due to the fact that frozen and homogenised SV 
instead of fresh IMA were used. In our study, we observed a significant increase in superoxide 
production after only 45 min of ET-1 exposure, suggesting the rapid stimulation of NADPH-
oxidase activity. To our knowledge, no studies performed on human vessels describe the 
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source of ET-mediated superoxide production and a possible intracellular pathway in the same 
study. A previous report shows that ET-1 increases the expression and activity of p47 phox in 
rat aortic rings via the ETA receptor, which would suggest that ET-1 is critically involved in 
the activation of NADPH oxidase.52 The suggested signalling52 The signaling pathway was the 
sequential activation of protein kinase C (PKC), c-Src and ERK ½. 
The following limitations were identified; first, the study cohort should ideally include healthy 
controls, not only because of differences in vascular pathophysiology but also due to ongoing 
medication such as statins, ACE inhibitors and beta-blockers, which will have specific effects 
on superoxide generation among patients. Second, the ET-mediated superoxide production 
was measured in vessels ex vivo and the present findings cannot be extrapolated to in vivo 
conditions. However, it is interesting that ET-1 also induces endothelial dysfunction in vivo 
via a mechanism that is related to oxidative processes. 91 Furthermore, ET-receptor blockade 
using BQ123 and BQ788 improves endothelial function in patients with coronary artery 
disease.92 93 Third, the small amount of tissue limits the opportunity for multiple observations 
in each patient. However, each observation was made from paired samples from the same 
patient and the study cohort was relatively large. 
5.3.1 Endothelin-1 and eNOS uncoupling
ET-1 is increased in the vasculature of patients with coronary artery disease94 95, almost 
abolishes endothelium-dependent vasodilation in healthy men96 and induces a marked 
increase in superoxide production in coronary artery bypass grafts (Study III). It is therefore 
important to further elucidate the mechanistic explanation behind these actions of ET-1 in 
order to increase our understanding and to develop new therapeutic strategies to prevent the 
detrimental effects of ET-1. Since it was suggested that ET-1 mediates superoxide production 
partly through uncoupled eNOS in the rat aorta 43, we wanted to investigate the link between 
ET-1 and biopterins in more detail. Although our initial findings showed no effect of eNOS 
inhibition when measuring ET-1-mediated superoxide, the link between eNOS uncoupling 
and ET-1 could not be ruled out. 
The main finding in Study IV was that ET-1 did not evoke any significant change in biopterins 
in sEnd.1 cells, HUVEC, ET-TG mice or coronary bypass grafts. Furthermore, BH4 was 
unable to inhibit ET-mediated endothelial dysfunction in resistance arteries from pregnant 
women and L-NAME pre-incubation followed by ET incubation did not affect ET-mediated 
superoxide production in coronary artery bypass grafts. Collectively, these findings suggest 
that ET-1 does not contribute to eNOS uncoupling in these tissues. One strength of this study 
was the advantage of using ET-TG mice with ET-1 overexpression in the endothelium. The 
long-term effects on biopterins of increased local endogenous ET-1 production in endothelial 
cells could be determined in the aorta, lungs and plasma. However, even though there is a three 
times higher vascular tissue ET-1 mRNA content and seven times higher ET-1 plasma levels in 
this model71, we were unable to see any effects on biopterins in these tissues. This may be due 
to the fact that this phenotype is relatively healthy without overt atherosclerosis. In addition, 
oxidative stress and NADPH oxidase are increased in this model which, together with our 
findings, collectively suggests that ET-1 affects NADPH rather than eNOS uncoupling in this 
model. 
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Increased ROS production is a key factor in disease progression and ET-1 contributes to 
this process, particularly in cardiovascular disease states such as coronary artery disease97. 
In Study III, it was observed that ET-1 was able to increase superoxide production, most 
likely via NADPH oxidase, in human coronary artery bypass grafts. It is possible that this 
increase in superoxide production could lead to the oxidation of BH4 and result in eNOS 
uncoupling or, alternatively, that ET-1 could have direct effects on biopterin synthesis via 
the induction of GTPCH. Zheng et al.46 describe a low renin hypertension model in rat, 
where exogenous ET-1 increases superoxide production in carotid arteries. In addition, in 
this model, L-NAME does not inhibit ET-induced superoxide production. Only apocynin and 
ET-receptor antagonism are able to inhibit this increase, indicating that the main source of 
superoxide induced by ET-1 is NADPH oxidase46, which was also the conclusion of Studies 
III and IV. 
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6   CONCLUSIONS
In this thesis we have studied the mechanisms of eNOS regulation in endothelial dysfunction 
from bedside to bench or intracellular level, studied the very key factors regulating eNOS 
uncoupling in the setting of patients, mouse models and endothelial cell models. 
In summary I conclude the following:
1- exogenous BH4 (oral) does not improve endothelial function due to increased levels 
of BH2 as a direct consequence of increased oxidation of BH4 and no net change in 
the ratio of BH4: BH2+B in patients with coronary artery disease. 
2- high levels of vascular BH4 is linked to improved endothelial function in patients 
with coronary artery disease. Chronic systemic inflammation leads to increased oxi-
dative stress and endothelial dysfunction. Acute inflammatory insult on the vascular 
wall leads to increased GCH-1 gene expression and increased vascular BH4 which 
in turn results in improved vascular function. This response is not seen in patients 
with deficient GCH-1 due to mutation in the GCH gene (GCH 1 X haplotype).
3- ET-1 increases superoxide production in patients with coronary artery disease via a 
receptor-dependent mechanism which involves NADPH oxidase.
4- ET-mediated superoxide does not change BH4 availability in the studied tissues and 
does not increase BH2. Endothelial dysfunction induced by ET-mediated superoxide 
production can therefore not be explained by eNOS uncoupling. 
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7   FUTURE PERSPECTIVES
During the course of my research, I wanted to address the question of oxidative stress in 
endothelial dysfunction, with the broader perspective of possibly shedding light on optimizing 
the treatment of patients with cardiovascular disease. Large antioxidant trials have failed to 
produce any outcome on hard end-points such as death or myocardial infarction. There are 
many review articles summarizing these neutral results98. Why then is it important to study 
oxidative stress? Is there any justification for antioxidants in the treatment of patients with 
coronary artery disease?
The role of oxidative stress becomes clear in the light of the importance of identifying 
and treating patients at risk of myocardial infarction. These are patients with endothelial 
dysfunction and other risk factors such as hypertension, hypercholesterolemia, diabetes and 
smoking. With improved knowledge of oxidative signaling, we can use the key enzyme 
systems as markers which will contribute to the diagnosis, prevention and treatment of 
cardiovascular disease. In a recent review, several important enzyme systems were identified. 
They could possibly be used in a clinical setting as redox biomarkers99, among these there is 
also the role of BH4 as a potential biomarker reflecting overall vascular redox status. ET-1 
is without doubt an important peptide in the progression of disease and, with current and 
future studies, it will be possible to foresee combinations of ET blockade with, for example, 
blockers of downstream signaling molecules involving ROS. 
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